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Investigating the pathogenesis of endometriosis through the use of 
Bioinformatics.  
 
ABSTRACT  
Usman Sajjad 
 
BACKGROUND 
 
Endometriosis is a common gynecological disease with unknown 
pathogenesis. There is a lack of clear understanding towards the 
pathogenesis and etiology of the disease, and as a result, a deficiency of 
effective treatment methods. Past theories and approaches have ignored 
interactions between genes on cellular level and how processes such as the 
immune system genetically can influence the development of the disease. 
 
HYPOTHESIS 
 
Bioinformatics, an evolving form of computational technology, can be used to 
systematically and methodically collate available information on gene 
expression and relevant transcription factors with aim of identifying the key 
players in the disease process.  
 
METHODS 
 
Genomic/Proteomic information was inputted into software programs such as 
Ingenuity IPA, GenEvestigator and Opossum. The software was able to 
produce network maps of biological pathways and meta-analysis plots of 
genes/proteins differentially expressed during endometriosis. Common 
regulatory transcription factors were subsequently identified for these up-
regulated genes. 
Immunohistochemistry (IHC) work was conducted to validate and analyze the 
expressional pattern of FOXD3 in endometrial samples of 20 patients (n=20). 
The expression in 10 normal fertile control endometrial samples (n=10) was 
compared to 10 endometrial samples from women with active peritoneal 
endometriosis at two different stages of the menstrual cycle (proliferative 
phase and window of implantation). The same sets of samples were used to 
 7 
compare any changes in expression of Androgen receptors (AR) and 
Progesterone receptors (PR), based on findings we obtained from our 
bioinformatics work. 
 
RESULTS 
 
We found FOXD3 to be the most common transcription involved in 
endometriosis, controlling 16 out of 38 up-regulated genes. SPP1, PTGS2, IL-
8, StAR and CXCR4 were found to be strongly up regulated in patients with 
endometriosis. The same pattern of up-regulation genes was seen in gastric 
cancer. AR and PR were seen to interact centrally with other genes/proteins 
in the Ingenuity IPA network map. 
From the IHC work, we found FOXD3 to be expressed in the luminal 
epithelium and glandular compartments of the normal proliferative 
endometrium. In patients with endometriosis, there was an increase in 
expression of FOXD3 in the luminal epithelium and glands of secretory 
endometrium.  
There was no significant difference between the expressional pattern of AR 
and PR in the endometrium of normal fertile control women and endometriosis 
patients.   
 
DISCUSSION 
We concluded FOXD3 to be a key player in the pathogenesis of 
endometriosis. The transcription factor was able to control up-regulated genes 
on a cellular level in various pathological processes, which contribute to the 
development of endometriosis. We propose future work is needed to extend 
the investigative measures of FOXD3 in the pathogenesis of endometriosis 
and elucidate how it can be a therapeutic target for treatment purposes in a 
clinical setting.  
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CHAPTER 1 
 
1- INTRODUCTION 
 
Endometriosis is a common gynaecological disease with unknown 
pathogenesis. The lack of clear understanding towards the aetiology and 
pathogenesis of the disease has resulted in a deficiency of novel and effective 
means to treat endometriosis. There is currently a general acceptance that 
the endometrium that lines the uterine cavity (eutopic) has a significant role to 
play in the pathogenesis of endometriosis. There were 8279 articles found 
when I carried out a Pubmed search with the words “endometriosis” and 
“pathogenesis” on 05/08/11. In most of these articles, the individual 
researchers discuss and show how one gene or a small group of genes, or 
gene products are aberrantly expressed in the endometrium of women with 
endometriosis and discuss how they may cause endometriosis. They may 
even test how the alteration of such gene(s) in one type of endometrial cells 
(usually endometrial stromal cells) alters their function in culture. However, 
this approach ignores the importance of interaction between all genes and 
gene products within a cell; cell-cell interaction within the endometrium and 
the effects of external influences such as the immune system on the 
endometrium to result in the pathological condition of endometriosis. 
  
Bioinformatics was used to systematically and methodically collate a vast 
amount of the available information on gene expression, gene function, gene 
products, and cellular function to identify the key players in endometriosis and 
also to predict suitable targets to treat the condition. Therefore, in my thesis I 
have reviewed the evidence available on the endometrial cellular aberrations 
associated with endometriosis and then with the use of bioinformatics I tried to 
understand how these processes are interconnected and interlinked. Then I 
discuss how I identified some transcription factors during this process which 
are likely to play a key role in regulating these functions. Since there have 
been no previous reports on these factors in human /animal endometrium, I 
then show how I progressed to test if one of these transcription factors 
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(FOXD3) is expressed in human normal endometrium and to investigate 
whetherit is aberrantly expressed in the eutopic endometrium of women with 
endometriosis.    
 
1.1-What is Endometriosis? 
 
Endometriosis is defined as the presence of endometrial tissue (both epithelial 
and stromal cells) outside the uterine cavity, usually on the pelvic peritoneum. 
(1) The tissue can also be found in areas such as the ovaries (known as 
endometrioma), as well as the rectovaginal septum, and occasionally, implant 
in the pleura and diaphragm. Symptoms  include pelvic pain and subfertility in 
women. The condition may be the result of biological or anatomical 
aberrations of the uterus. (1) Endometriosis is an oestrogen dependent 
chronic inflammatory disease that affects approximately 2 million women in 
the UK (1).  
 
It has been estimated the disease occurs in roughly 5-10% of women (1) 
Studies have shown 50-60% of women and teenage girls had pelvic pain, and 
there are 50% who suffer from infertility. (2) It is not normally seen before the 
age of 15 in women or after menopause. (3) However, in recent years patients 
who are under the age of 20 have been identified with endometriosis due to 
the use of laparoscopy in the diagnosis for patients with symptoms suggestive 
of the disease. (3)  
 
1.1.1- Epidemiology (Prevalence and Incidence) of Endometriosis 
The prevalence of a condition is the total number of cases for a condition i in 
the population at a given time. The incidence of a condition is the number of 
new cases over a period of time, being expressed as a rate. (4) Often groups 
of endometriosis patients are compared for the measures of prevalence and 
incidence, such as 
1. Symptomatic patients with endometriosis undergoing laparoscopy  
2. Infertile patients 
3. Asymptomatic patients undergoing procedure unrelated 
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Infertile patients usually possess the highest prevalence rates ranging from 5-
45%. (4) Patients admitted for pelvic pain have a prevalence rate of 5-20% (4) 
Generally the true prevalence of the condition in the general population is 
unknown as the diagnosis is based on surgical visualisation which has 
hindered general epidemiology rates. Variations may occur in the estimates of 
prevalence rates, with there being differences in the severity of symptoms in 
patients and with some patients being asymptomatic. (4) Additionally, 
variations in the age at which childbearing occurs in different populations can 
also cause differences in prevalence rates. The estimated prevalence in the 
general population is 1.5-6.2% and the age of incidence peaks at 40 years 
old. (4) Clearer details into the epidemiology of endometriosis have, however, 
emerged over the past decade due to advances in diagnostic technology. 
Some studies have estimated the prevalence to be around 4% of 
asymptomatic endometriosis patients. (112) Cramer et al in 2002 showed that 
in the UK 1.3 per 1000 females aged 15-44 years old were diagnosed with 
endometriosis after the use of advancing diagnostic technology. (5)  
Another study by Leibson et al in 2004 reported that out of 8229 women 
diagnosed by the Rochester Epidemiology Project surgical index, the surgical 
diagnosis of endometriosis was 11.5% of women over the age of 15 years old, 
and the rate was higher in women aged 45-54 years old. (6) The highest rate 
of newly diagnosed endometriosis was seen in women between the ages of 
25-34 years old. (6)  
1.1.2- Effects of endometriosis on society and health care costs  
There have been several studies investigating how endometriosis-related 
symptoms mpact on the physical and mental health of women and on their 
quality of life. (7) Numerous studies have shown how endometriosis patients 
had an average of 7.4 hours lost of working time during the week due to the 
severity of their symptoms. Additionally, 64% of patients had reduced 
productivity and 60% of patients reported their daily activity had been 
impaired due to endometriosis. (7) Endometriosis can cause depression in 
some patients due to the chronic pelvic pain caused, as well as the bowel and 
bladder symptoms it may result in. (7) Therefore, it is clear the symptoms can 
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be a substantial burden on a patient’s life. (7) As well as incurring a cost of 
almost £2.8 billion a year (due to days taken off from work), a survey in 2005 
showed  an 8 year delay in patients being diagnosed from the time they first 
presented with their symptoms. (7) 
 
 
1.2- Signs and Symptoms of Endometriosis 
 
Prior to menstruation, the endometrium thickens in response to ovarian 
hormones. Absence of pregnancy, degeneration of the corpus luteum and a 
resulting drop in circulating progesterone causes a break down and shedding 
of the superficial layer of the endometrium. (8) The menstrual flow is known to 
contain a many inflammatory chemicals (such as prostaglandins, cytokines IL-
8, SPP1 (secreted phosphoprotein 1), and others). (8) After menstrual 
shedding the endometrial tissue undergoes repair, under the influence of 
hormones. However, in the hypothesis of the pathology of endometriosis, the 
ectopically situated endometrial tissue and  inflammation inducing agents 
produced during the regeneration process have no way of leaving the body, 
therefore becoming trapped within the pelvic cavity causing symptoms 
associated with endometriosis. (8) 
 
The symptoms that arise depend on the site of active endometriosis but 
generally endometriosis causes a variety of symptoms including severe pelvic 
pain, painful periods, painful sexual intercourse and infertility. (9) The 
inflammation involved in endometriosis can stimulate pelvic nerve endings 
causing pain and may also impair the Fallopian tube function as well affecting 
the development of oocyte and embryo. (9) 
 
1.2.1-Pelvic Pain 
Pelvic pain is a major symptom in patients with endometriosis. (10) The pain 
may be mild to severe cramping that occurs in the pelvic area, lower back and 
rectum, progressing to a chronic pain. (10) However, the amount of pain 
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experienced by women may not correlate with the stage of the condition. (11) 
Some women may have little pain despite having the condition with extensive 
scarring. Roth et al in 2011 investigated women suffering from chronic pelvic 
pain secondary to endometriosis and compared this to women with chronic 
pelvic pain without the disease. (11) The study found no “psychological 
disturbance” for women with chronic pelvic pain due to endometriosis. (11) 
Other symptoms may include dysmenorrhoea, which is a painful, cramp-like 
pain during menses, getting progressively worse over time. (12) 
Dysmenorrhoea can include primary and secondary dysmenorrhoea and 
occurs in 60% of women with endometriosis. (13) Primary dysmenorrhoea 
usually begins shortly after the first menstrual cycle and will persist until the 
menopause in the affected women. (13) Therefore, many studies believe 
primary dysmenorrhoea to be an early sign or manifestation of endometriosis.  
(13) Other symptoms can also include dyspareunia (painful sexual 
intercourse) as well as dysuria (urinary frequency and urgency). (14) Gnawing 
and throbbing pain is also common in patients with endometriosis, and those 
with a deeper disease compared with superficial, have complained about a 
greater shooting rectal and pelvic pain. (14)(15) Symptoms reported by some 
patients have included painful bladder syndrome, irritable bowel syndrome, 
fibromyalgia, and migraines. (15) 
1.2.2- Infertility  
Several mechanisms have been proposed to provide a possible explanation 
into why patients with endometriosis suffer with infertility. (16) Inflammatory 
changes during endometriosis in the pelvic cavity may affect the peritoneal 
fluid, which may result in a release of pro-inflammatory factors. The changes 
to the peritoneal fluid can affect the sperm-oocyte interaction according to 
some studies. (17) (18) Some published data suggested that the peritoneal 
fluid from women could cause the immobilisation of sperm due to the action of 
macrophages and Interleukins 1 and 6. (17) (18) Fertilisation of human 
oocytes takes place at the distal end of the fallopian tube, and the ampulla of 
the fallopian tube is exposed to the peritoneal fluid from the pelvic cavity. (17) 
Studies have also indicated how the increase in inflammatory mediators 
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during endometriosis such as TNF-Alpha may cause DNA damage to sperm. 
(19) 
Infertility can also be due to dysfunctions in the ovary in patients with 
endometriosis. With endometriosis extended to the ovaries in some cases, 
endometriotic cysts can reduce the function of available ovarian tissue. 
Therefore, there may be a reduced response to ovarian hyperstimulation. (20)  
Findings have also shown how the endometrium in the uterus may be altered 
in patients with endometriosis, possibly affecting fertility in the process. (21) 
The activation of steroidogenic factor 1 enables prostaglandins to start the 
expression of aromatase CYP19A1, which leads to  in situ production of 
oestrogen. (21) This activity may have an effect on the peristaltic activity of 
the myometrium and a resistance to progesterone.  These changes in the 
endometrium,  may  result in impaired implantation of the oocyte, presenting 
possible issues of infertility. (21) In addition, women with endometriosis have 
an increased concentration of IgG and IgA, and these antibodies may affect 
embryo implantation. (18) 
Through the study of bioinformatics, we will be studying some of these 
molecular changes mentioned in women with endometriosis, with the aim of 
providing a possible explanation. Altered immune response and embryo 
implantation, as well as oestrogen responsiveness and progesterone 
resistance will be aspects of endometriosis that we will be looking further into, 
as well as the genes involved in these processes.  
1.3- Diagnosis of endometriosis 
 
Diagnosing endometriosis is a problem in today’s primary care setting 
because patients present with symptoms that are difficult to differentiate from 
other conditions. Many patients may be misdiagnosed with pelvic 
inflammatory disease or idiopathic dysmenorrhoea because after  menarche, 
they often present with symptoms associated with menstruation such as a 
painful period. (22) Therefore, due to the non-specific nature of endometriosis 
symptoms, problems are created at a clinical level for a general practitioner. 
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(22) 
 
A large proportion of patients are diagnosed after laparoscopy having had the 
condition asymptomatically. Symptoms, as mentioned earlier, may develop as 
early as 15 years old in patients and persist beyond the menopause. (22) 
Some symptoms are reported more commonly than others. Below is a table of 
symptoms along with the percentage of women presenting with the 
symptoms. These findings were based on a study conducted by Louden et al 
in 1995. (23) 
 
Symptom Percentage of women with 
endometriosis presenting with the 
symptom. 
Dysmenorrhoea  40-80 
Bloating 42 
Lethargy 40 
Chronic pelvic pain 20-80 
Constipation 29 
Lower Back Pain 29 
Deep dyspareunia 19-42 
Infertility  9 
 
Upon diagnosis, a pelvic examination may be normal but findings may include 
tenderness in the uterine area, nodularity of the uterosacral ligament and a 
fixed retroverted uterus. (24) The tenderness often presents difficulty in being 
able to spot the other features. (24) Additionally, many patients who suffer 
from fibroids or adenomyosis may also have dysmenorrhoea therefore a 
diagnosis based on a history of presenting complaint may not be conclusive. 
(25)  
 
With difficulty diagnosing patients with endometriosis due to the frequent 
asymptomatic nature and in some cases symptoms resembling other 
conditions, investigative measures are undertaken clinically. 
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The gold standard diagnostic test of endometriosis is surgically visualising  
ectopic lesions of the pelvis at laparoscopy, which is an invasive technique. 
(24) Endometriosis is usually confirmed through surgery. (26) Nezhat et al in 
1994 showed that out of 91 patients with endometriosis who complained of 
chronic pelvic pain, all had a normal pelvic examination with no tenderness or 
any positive clinical finding. (26) However, 47% of patients were identified to 
have active endometriosis after laparoscopy. (26) 
 
Presence of endometrial glands, endometrial stroma, epithelium and 
hemosiderin macrophages are required before a conclusive diagnosis is 
made. (27) Lesions found are most likely to be large and have mixed colour in 
the pelvic cul-de-sac or utero-sacral ligament region. (28) However, studies 
such as that by Walter et al in 2004 have shown only 55-65% of patients with 
endometriosis lesions are confirmed through histopathology, and 18% of 
patients suspected to have endometriosis have no abnormalities identified in 
the surgically collected biopsies of the ectopic lesions pathologically. (29) 
Attempts should be made to reach a diagnosis based on taking a history and 
a clinical examination, rather than immediately proceeding to giving the 
patient the option of undergoing a laparoscopy. 
Transvaginal sonography (TVS) has been used as a non-invasive 
assessment for patients with pelvic problems.  Studies have shown TVS to be 
a sensitive tool for detecting endometriosis in the ovary. (26) Ovarian 
endometrioma presents with persistent circular tissue with a demarcation from 
the ovarian parenchyma. (26)  
 
Moore et al in 2002 reviewed 67 papers on the use of TVS for detecting pelvic 
endometriosis. It was concluded TVS is a useful diagnostic test for the 
identification of cystic ovarian endometriosis before surgery, with the 
prevalence of the condition ranging between 13-40%. (30) Other recent 
studies have showed how TVS could be used for detecting endometriosis in 
the uterosacral ligament, the pouch of Douglas and the vagina. (31) TVS is 
readily available, and is a cost and time effective diagnostic tool, when 
compared to other procedures such as Magnetic resonance imaging (MRI). 
(31) TVS can also be used to detect deep infiltrating endometriosis in 
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patients. (31) Deep endometriosis implants present with regular masses with 
partings in the centre defined as an “Indian Head dress”.  (32)  
 
Recent advances have offered ideas for 3-D sonography, which could 
increase the accuracy of the assessment of deep endometriosis in diagnosis.  
A study by Bazot et al in 2003 suggested transvaginal ultrasound could also 
diagnose colorectal endometriosis, showing if the muscularis propria has 
been infiltrated in a patient. (32) 
Serum markers have also been studied in relation to detecting endometriosis 
in various past studies. May et al in 2010 investigated the availability of 
peripheral biomarkers in endometriosis. The study highlighted the delay in 
making a diagnosis, and the advantages that the availability of biomarkers 
which may help a clinician diagnose and treat endometriosis in patients would 
bring. (33) Any marker found could avoid unnecessary diagnostic procedures 
and allow for cost-effective treatment plans. Therefore further research is 
needed before one biomarker can be recommended for clinical use. (33) We 
plan to build on  past work and investigate potential biomarkers and 
transcription factors, with the aim of discovering whether they could be used 
for diagnosis and treatment in the future.  
1.3.1- Clinical Staging of Endometriosis 
Endometriosis can be staged I–IV during surgery according to the American 
Society for Reproduction. (34) The staging system assesses adhesions or 
lesions in the pelvic area and stages the level of the disease. (34)   
 
Stage I (Minimal) - The findings are usually only superficial lesions and very 
few adhesions.  This is peritoneal endometriosis. 
Stage II (Mild) – There is superficial but some deep lesions are found in the 
cul-de-sac. 
Stage III (Moderate) - Superficial, adhesions and deep lesions are present as 
well as endometriomas. 
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Stage IV (Severe) – All the above are present, as well adhesions and large 
endometriomas. 
 
The staging system does not show the level of pain and infertility. Patients 
may have stage 1 endometriosis whilst  experiencing severe symptoms such 
as pelvic pain and infertility.  
 
1.4 Treatment of Endometriosis 
1.4.1- Medical Treatment  
The aim of medical treatment in patients with endometriosis is to halt the 
growth of endometriosis lesions. The most common medical treatment is the 
use of gonadotropin-releasing hormone (GnRH) agonists and oral 
contraceptives. (35) This treatment is carried out in patients whom have had a 
confirmation diagnosis and have had surgical  excision, and require long-term 
management. (35) Oral contraceptives are taken indefinitely, being effective in 
treating dysmenorrhea. They can help relieve milder symptoms and can be 
taken over long periods of time. 
  
A study showed how in 57 patients, after 6 months, oral contraceptives 
reduced the severity of dysmenorrhea compared to GnRH agonists. (36) 
Pathologically, oral contraceptives cause atrophy of the endometrial tissue; 
whilst GnRH agonists cause a down-regulation of the pituary-ovary axis so 
there is a state hypoestrogenism (reduced oestrogen production). (36) GnRH 
agonists are taken as a nasal spray, implant or an injection, and are taken 
continuously over two weeks.  Side effects include hot flushes and vaginal 
dryness. (36) 
 
Androgens can induce atrophy of the endometrium, and danazaol (synthetic 
derivative of 17α-ethinyltestosterone) acts to increase the concentration of 
circulating testosterone, which is able to inhibit luteinizing hormone (LH) 
surges and estrogen production from the ovary. (36) An artificial menopause 
is induced, contributing to the inhibition of ectopic and eutopic endometrial 
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growth. (36) The fourth hormone taken as part of the medical treatment is 
medroxyprosterone acetate, which is a type of progestogen. The hormone 
behaves like progesterone, preventing ovulation, so the endometrial tissue 
shrinks. (36)  
 
Non-steroidal anti-inflammatories (NSAIDs), such as ibuprofen may also be 
used to prevent inflammation (pain, tenderness and swelling) from 
endometriosis, relieving any discomfort and pain. (36) 
 
Hormone production, as can be seen, limits the production of oestrogen in the 
body; therefore endometrial tissue size is reduced so symptom severity is 
lessened. However, medical treatment does not have any effect on the 
adhesion of ectopic endometrial tissue and can also decrease fertility.  
1.4.2- Surgical Treatment 
 
Hormone therapy is not effective in combating the effects of endometriosis on 
other organs and therefore laparoscopic surgery (mentioned earlier in 
chapter) may be needed to remove endometrial tissue growth and scar tissue. 
(37) Surgical therapy can be performed alongside diagnostic laparoscopy. In 
the advanced stages of endometriosis (Stage 3 or 4 according to the 
American Fertility score), laparoscopic surgery is used to remove visible 
endometrial implants and divide scar tissue. (37) This is because lesions 
larger than 3cm respond poorly to hormonal treatment so surgical intervention 
is needed. The laparoscope is inserted into the pelvic cavity through a small 
cut near the naval, and a light source allows the gynaecologist to view the 
organs in the pelvic region and any ectopic endometrial tissue implants 
present. (37) A laparatomy is a procedure in which a larger cut (10-15cm) is 
incised into the abdomen if the severe endometriosis cannot be treated by 
laparoscopy. If minimal to moderate endometriosis is found, a diagnostic 
laparoscopy can be combined with an operative laparoscopy. (37) 
 
The removal of the uterus (hysterectomy) or removal of the ovary 
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(oophorectomy) may be an option depending on the severity of the condition 
as well as the age of the patient. (37) 
A Cochrane review conducted by Furness et al in 2011 reviewed the “Pre and 
Post Operative medical therapy for endometriosis surgery”. (38) There was no 
evidence of benefit associated with post surgical medical therapy and there 
was not enough evidence to determine whether there was a benefit for pre-
surgical medical treatment. (38) 
 
With no treatment suitable for all patients and not effective in some cases, 
more understanding is needed regarding the pathogenesis of the condition. 
Even though there is not a full understanding of the aetiology and 
pathogenesis of the condition, there are available theories and explanations 
that have been put forward by studies in the past few decades. 
 
1.5- Aetiology and Pathogenesis of Endometriosis 
The most commonly held theory on its aetiology is that retrograde 
menstruation and trans-tubal migration of viable endometrial fragments occurs 
into the pelvic cavity where they attach to and invade the peritoneal 
mesothelium establishing ectopic growth of endometrial tissue (39). Given 
that most women reflux menstrual effluent into the peritoneal cavity during 
menstruation, and endometriosis only develops in 10-15% of women, it is 
unclear why some women develop endometriosis whilst others do not. (39) 
Endometriosis is diagnosed in 20% of women who have undergone 
laparoscopy for pelvic pain or infertility. (39) The pregnancy rate in women 
with endometriosis is about half that of women with tubal factor infertility and 
decreases as the severity of endometriosis increases (39). 
There are three theories of the pathogenesis of endometriosis. The 
Sampson’s Theory was originally devised in 1920 and states that during each 
menstruation; some of the blood goes in the opposite direction and flows out 
of the fallopian tubes, proposing endometrial fragments are spread by 
retrograde menstruation through the fallopian tubes into the peritoneal cavity. 
(40) The theory states that as the blood is flowing out towards the fallopian 
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tubes, it carries cells from the lining of the uterus. These cells eventually 
implant onto the surface of the pelvis and grow to form ectopic endometrial 
implants, accounting to the development of endometriosis.  (40)  
 
The pattern of endometriosis supports this theory and endometrial fragments 
gravitationally move to the area of the pelvis including the ovary, utero-sacral 
ligaments and the fallopian tubes (41). The endometrial fragments will 
implant on the peritoneal surface and causes an inflammatory response, 
followed by angiogenesis, adhesion, fibrosis and scarring. (41) 
Endometriosis can also be inherited polygenically, with evidence of linkage to 
chromsomes 7 and 10. (41)  
 
The second theory of pathogenesis is the coelomic-metaplasia hypothesis 
and this suggests that there is a differentiation of mesoepithelial cells into 
endometrial like tissue. (42)  
 
A third theory suggests that the menstrual tissue from the endometrial cavity 
can spread to the rest of the reproductive system via lymphatic vessels and 
veins, and that circulating blood cells originating from bone marrow can 
differentiate into endometriotic tissue at various sites. (41) This is supported 
by some patients possessing deep rectovaginal endometriosis showing that 
the disease can spread via the lymphatic system, as well as cells being 
present in other parts of the body. (43)  
Endometriosis produces inflammatory mediators, which cause pain and 
inflammation resulting in scarring of surrounding tissue. (41) 
Other possible environmental factors can cause endometriosis. There have 
been studies to show Dioxin exposure to be a likely cause of endometriosis, 
with Rier et al study in 1993 showing 80% of monkeys had developed 
endometriosis from receiving a dose of dioxin. (44) The study also outlined 
how other pesticides may produce a hormone imbalance, possibly 
contributing to endometriosis. (44) 
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Studies have also shown that the risk of endometriosis may be reduced in 
smokers. (45) Somigilana et al in 2011 showed that smoking causes a 
decrease in estrogen with increased bleeding and shorter luteal phase. (45) 
With endometriosis being an estrogen related disease, this may be a plausible 
link. 
 
With commonly existing theories into the etiology of the condition present, 
various biological processes that are affected by endometriosis provide us 
with a possible explanation into the pathogenesis of the condition. We looked 
to use the genetic molecular information found from different pathological 
processes involved in endometriosis (obtained from a PubMed literature 
search) and use this in a bioinformatics approach. This was able to direct us 
later in the research project to gain a better understanding of the 
pathogenesis of the condition and provided information on key players, which 
may be targeted for future treatment purposes. 
 
1.5.1 Molecular aspects and physiology of the normal endometrium 
 
The endometrium is the innermost glandular layer and functions as the lining 
for the uterus. During the menstrual cycle, the endometrium will grow and 
thicken to form a glandular like tissue layer, presenting an optimum 
environment for the blactocyst to implant upon it arriving to the uterus. (16) 
The endometrial glands and blood vessels in the endometrium increase in 
size and number during pregnancy. The molecular mechanisms of 
implantation in the normal physiology are only partially understood. There is a 
cascade-like interaction between the embroyonic trophoblast cells, epithelial 
cells, decidual cells, the extra-cellular matrix (ECM) of the maternal 
endometrium and the cells responsible for immune reactions in the normal 
endometrium. 
 
The blastocyst secretes molecules such as EPF (early pregnancy factor) and 
HCG (human chorionic gonadotrophin), which affect the activity of the 
endometrium and ovaries. Cadherins are cell adhesion molecules which play 
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a role in anchoring the blastocyst in its route towards the endometrium in the 
pre-implantation stage. (16) The embryo will produce interleukin 1 (IL-1) which 
is important in orientating the embryo towards the endometrium. The embryo 
also produces Platelet-activating factor (PAF). In the pre-implantation phase, 
the glycocalyx (surface proteins) and the decrease in the electrostatic 
repulsion between the blastocyst and the endometrium, allows for the 
facilitation of implantation in the normal endometrium.  (17) The secretion of 
implantation factors, Interleukin 1 (IL-1), the inhibition factor for leukocytes 
(LIF), colony-stimulating factor (CSF), as well as the epithelial growth factor 
(EGF) and its receptors (EGF-R), allow for adhesion of the blastocyst onto the 
uterine epithelium. 
 
During implantation in the normal endometrium, IL-1 binds on the receptors at 
the surface of the epithelial cells. LIF is synthesized on the 18th day of the 
menstrual cycle and the receptors are expressed on the blastocyst.  
 
Upon implantation, the basal membrane of the trophoblast is destroyed and 
grows into the decidua of the uterine tissue. The cells of the trophoblast 
secrete enzymes such as MMP (Matrix Metalloproteinases) and plasminogen-
activators. The trophoblastic cells express integrins on the cell membrane and 
these are able to interact with the uterine muscoca. Subsequently, the 
trophoblast is able to grow into the endometrium and the extra-cellular matrix 
is able to decompose under the influence of endometrial factors that are 
secreted by epithelial cells, fibroblasts, macrophages and leukocytes. These 
factors, which may be aberrantly up or down regulated in patients with 
endometriosis, can cause an autocrine and paracrine effect on the normal 
endometrium. 
 
In patients with endometriosis, these outlined molecular activities observed in 
normal endometrium may be notably different.  
1.5.2- Molecular aspects and physiology in endometriosis 
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1.5.2.1- Increased cell adherence 
Endometrial cells in women with endometriosis have been shown to 
demonstrate increased adherence to peritoneal cells. Griffiths et al in 2010 
shown how there is an increased expression of CD44, which is an important 
cell adhesion protein. (46)  
According to many other studies (Morin 1999), increased cell adherence 
signaling has been demonstrated in endometriosis. (47) (48) The study shows 
that there is an increase expression of cell adherence molecules and 
enzymes such as Beta catenin, E-Cadherin and P-Cadherin. (47, 48) 
Increased cell adherence possibly plays a major role in the Sampson’s theory 
of retrograde menstruation with endometrial fragments being found outside 
the uterine cavity, and the involvement of molecules such as CD44 may play 
an important role in that. We searched for genes and proteins involved in 
adherence through our literature search of “retrograde menstruation”. 
1.5.2.2-Metastasis 
Since endometrial tissue survives in unusual locations (outside of the normal 
site of uterine cavity) it can be regarded as a metastatic disease. However, 
endometriosis is not fatal or malignant. Described as a benign metastatic 
disease, we reviewed studies to discover any genes that are involved in 
metastatic changes within patients with endometriosis. Metastasis is the 
spread of a disease from one organ to another or to an adjacent part of 
another organ. (49) Endometriosis exhibits features of adherence, invasion 
and metastases. (49) Endometriosis can be characterized in patients 
histologically by endometrial glands with cytological atypia, and has been 
observed in 12-35% of ovarian endometriosis cases. (50) There have been 
seen to be many similarities in the metastases involved in endometrial cancer 
and endometriosis.  Invasive cancer is distinguished from non-invasive cancer 
through the ability of cells to invade through the basement membrane. (50) 
Endometrial carcinomas have been seen to secrete proteases and expression 
of these proteases such as matrix metalloproteinases-2 (MMP-2) and matrix 
metalloproteinase-9 (MMP-9) can be linked to grading and stages of the 
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cancer. (50) Similarly in endometriosis, MMP activity has been shown to be 
up-regulated in endometriosis patients.  (50)  
Specifically, MMP-1 and MMP-2 are increased within the eutopic 
endometrium of patients with endometriosis. (51) Local MMP factors such as 
MMP-1, MMP-2 and MMP-9 can degrade the extracellular matrix of the 
endometrium and cause vascular rebuilding, resulting in a migration of 
endothelial cells. (52)  
Studies such as that of Ning et al in 2006 showed that there is higher 
expression of MMP 1, 2, and 9 in the eutopic endometrium of women with 
endometriosis compared to normal patients.(53) The expression of MMPs is 
controlled by cytokines and steroid hormones in women. MMP-1 is detected 
during the early stages of the menstrual cycle, whereas MMP-2 is expressed 
during the entire menstrual cycle. (54) 
Therefore we can predict MMP molecules have a role in the pathogenesis of 
endometriotic lesions and metastatic activity. 
1.5.2.3- Proliferative Activity  
In endometriosis, patients have been seen to possess increased levels of 
endothelial growth factor molecules. Studies such as that by Burlev et al in 2010 
indicated how patients have elevated levels of vascular endothelial growth factor 
A (VEGF-A), VEGF-1 and VEGF-2. Therefore there is increased angiogenesis 
activity in patients. (55) Other studies from the same author mentioned above 
investigated apoptosis and proliferative activity in the glandular epithelium of 
the endometrium in patients with endometriosis. (56) The study investigated 
whether the proliferative activity of the glandular epithelium in the proliferative 
phase of endometriosis was higher than that in the secretory phase. (56)  
Studies have shown the increase in expression of specific molecules have 
had an effect on the proliferative activity of the endometrium in women with 
endometriosis compared to those who do not have it. Park et al in 2009 
examined 631 infertile women, including 197 without endometriosis and 434 
with the disease. (57) It was found there was an increased expression of Ki-
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67 in assay results from patients with endometriosis. (57) Therefore, there 
was seen to be an increased proliferative activity in patients. (57) 
As mentioned earlier, it is known physiologically the endometrium thickens 
during the proliferative phase of the menstrual cycle in response to oestrogen. 
During ovulation, the endometrium will provide a host for the attachment for 
the early embryo until the placenta develops into the early stage of 
pregnancy.  Studies such as that of Jason et al in 2008 investigated how in 
the infertile population, there may be a defect in the proliferative phase of 
endometrium under the influence of Follicle Stimulating Hormone (FSH). (58) 
In the proliferative phase, FSH is secreted by the anterior pituitary gland. (58) 
The secretion rises in the last few days of a women’s menstrual cycle and this 
rise will cause the production of ovarian follices. FSH causes proliferation of 
granulosa cells in the developing follices and an increase in the expression of 
luteinizing hormone (LH) in the granulosa cells. (58) The granulosa cells will 
begin to secrete oestrogen.  
Jason et al’s study in 2008 investigated how patients with a diagnosis of 
PCOS (Polycystic Ovarian Syndrome) or endometriosis achieved a lower 
peak endometrial thickness than control subjects in the study. (58) However, 
Zhang et al in 2010 discovered that 17β-estradiol promotes cell proliferation in 
the endometrium in endometriosis by activating the PI3K/AKt pathway via an 
NFκB/PTEN-dependent pathway. (59) 
1.5.2.4- Apoptosis  
Apoptosis is a biological process involving programmed cell death within 
organisms. (60) This process eventually leads to cell changes and death. (87) 
The changes include DNA fragmentation and cell shrinkage, as apoptotic 
bodies are produced. (60) (61) Apoptosis is important in removing senescent 
endometrial cells from the functional layer of the endometrium. (62) 
Senescence is the morphological change in a cell or organism after it ages. 
Apoptotic bodies are able to remove cell contents after being engulfed by 
these bodies. (61) Apoptosis, therefore, is important in removing senescent 
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cells. (62) The process is important in the normal endometrial function during 
the menstrual cycle in maintaining homeostasis. (61) Studies have shown that 
there is decreased apoptotic activity in the endometrium of women with 
endometriosis compared to patients who do not have the condition. (61) 
Therefore, there is a decreased removal of unwanted cells, and there is an 
increase of cells in the endometrium.  
 
As mentioned before, the higher expression of Bcl-2 has an effect on the 
decreased apoptotic activity in patients with endometriosis. With endometrial 
cells from patients having a greater ability to implant and survive elsewhere 
ectopically due to increased proliferation, the lower apoptosis activity allows 
for these cells to survive longer. Studies, such as that by Meresman et al in 
2000, investigated that there was a decrease in expression of apoptotic 
bodies such as BAX and an increase in expression of Bcl-2, which is an anti-
apoptotic factors. (63) BCL-2, a molecule seen to be elevated in patients with 
endometriosis, encodes an outer mitochondrial membrane protein 
suppressing apoptosis in numerous cells. (63) Bcl-2 is seen to work in a 
feedback system with caspase molecules, by inhibiting caspases. (89) Other 
members of the BCL group are seen as pro-apoptotic (promoting apoptosis), 
whilst other’s such as BCL-2 and Bcl-xl mentioned to be elevated in patients 
with endometriosis, are anti-apoptotic. (63) 
 
Therefore, the increase in proliferation and decrease in apoptosis with more 
endometrial cells being present to be refluxed supports Sampson’s theory 
mentioned earlier. Genes related to apoptosis such as GADD454 and 
GADD45B have been found to be down regulated in the endometrial tissue 
according to a study conducted by Eyster et al in 2007. (64)  
With studies showing a promotion of cell proliferation of the endometrium in 
patients and a decrease in apoptosis, we decided to look into genes and 
molecules that were involved with this. From there, we used bioinformatics 
technology to investigate how these genes may be linked to other genes 
involved in pathological processes in patients with endometriosis. This is 
important because the genes mentioned in previous studies eg BCL-2, BAX 
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etc play an important role in proliferation and apoptosis, and could lend 
support to some of the suggested theories of pathogenesis such as 
retrograde menstruation. With studies showing clear differences in 
endometrial cell activity between women with endometriosis compared to 
normal patients, conducting Pubmed searches to discover genes that are 
responsible was important. These searches to find more genes and molecules 
helped provide a greater insight into the pathogenesis of the condition. 
 
1.5.2.5- Oestrogen responsiveness 
 
I conducted searches on studies that have investigated oestrogen 
responsiveness and its involvement in endometriosis. It is known that 
granulosa cells secrete oestrogen and the increased levels of oestrogen 
(during the proliferative phase of the cycle) stimulate the production of 
gonadotropin-releasing hormone (GnRh), and this also increases the 
production of LH. (61) The increased production in LH stimulates the 
production of androgens in thecal cells of the endometrium and stimulates 
proliferation of endometrium, therefore the rising levels in the blood cause 
growth of the endometrium and the myometrium in the uterus. (61) As well as 
being secreted by the ovaries, peripheral formation from the increasing 
concentration of circulating estrone sulphate can also increase the amount of 
oestrogen. (65) Studies have shown that there is abnormal expression of 
oestrogen-metabolizing enzymes resulting in high estrogen-2 (E2) 
biosynthesis leading to increased proliferative activity of the endometrium in 
patients with endometriosis. (65) The oestrogen formed (E2) will bind to both 
oestrogen receptors (ERα and ERβ). (66) 
 
In patients with endometriosis, studies have shown that there is higher 
expression of ERα compared to that of ERβ in the eutopic endometrium of 
endometriosis patients. (94) The levels of both of these receptors are higher 
in the proliferative than the secretory phase. (94) The levels of ERβ are higher 
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in the ectopic endometrium due to abnormal DNA methylation of the promoter 
gene for the ESR2 receptor. (67)  
 
Rizner at al in 2009 studied oestrogen metabolism and the effect of 
endometriosis. (68) It is known that endometriosis will progress in an 
oestrogen-dependent manner, according to Kitawaki et al in 2003 who 
showed that an increase of oestrogen can cause a relapse of endometriotic 
lesions. (69) Other studies such as that by Takahashi et al found that patients 
with endometriosis were found to have higher levels of estradiol (E2) in 
comparison to healthy women.  
The rise in oestrogen also causes endometrial cells to produce progesterone 
receptors, helping the endometrium to respond to rising levels of 
progesterone during the late proliferative phase. (69) 
 
Therefore, we were able to find any possible genes or molecules related to 
oestrogen responsiveness in patients with endometriosis, with aim of helping 
us achieve a greater understanding of the condition on a molecular and 
genetic basis. 
 
1.5.2.6- P450 Enzymes 
 
P450 is a cytochrome and is part of a large group of enzymes. They function 
by catalyzing the oxidation of substances such as lipids and steroid 
hormones. (70) P450 enzymes use large and small substrates in enzyme 
reactions, and are at times part of electron transfer chains. (70) In the same 
paper mentioned earlier by Kitawaki et al, the aromatase cytochrome P-450 
was studied and its possible detection as a diagnostic test for endometriosis. 
(69) It was found that the expression of aromatase cytochrome P-450 in 
biopsy specimens of eutopic endometrium in patients with endometriosis is 
distinguishable from patients who do not have the condition, in which P-450 
was not expressed. (69) Therefore it is also vital we investigate microarray 
studies that have studied P-450 and patients with endometriosis. 
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Other papers have shown how there is increased expression of the mRNA of 
the aromatase enzyme in the ectopic endometrium of patients with 
endometriosis. Studies by Aghajanova et al in 2009 and Smuc et al in 2007, 
showed increased expression of P450 enzymes in ovarian, deep and 
peritoneal endometriosis. (71) However, according to Heilier et al in 2006, 
higher levels of aromatase p450 enzymes were found in ovarian 
endometriosis, compared to that of peritoneal and deep endometriotic 
nodules. (72) In ovarian endometriosis, over-expression of the P450 
aromatase enzymes assists the catalyzing of androstenedione to estrone 
(estrogen), as well as testosterone to estrogen-2 (E2). (72) Therefore, this 
indicates the P450 enzyme is important in the synthesis of estrogen and we 
used this as a search category to find particular genes or molecules that were 
involved in the pathways of P450 and estrogen synthesis.  
 
1.5.2.7- Prostaglandins 
 
Prostaglandins (PGE2) are lipids that are important in producing an autocrine 
or paracrine response through binding to a G-protein coupled receptor to 
activate intracellular signaling. (73) There is great importance in ovulation, 
implantation and menstruation. Prostaglandins are also important in 
augmenting contractions within the uterus, through increasing intracellular 
calcium ions.  They also interact with involvement of oestrogen and fibroblast 
growth factors (FGF)-9 production. (73) Subsequently, angiogenesis is 
promoted as endothelial cells are recruited to form new vasculature so in 
every menses, prostaglandins contribute to tissue repair, growth and 
differentiation within the uterus. (73)  
 
Prostaglandins are produced through the conversion of arachidonic acid to 
prostaglandin H2 and this is regulated by cyclooxygenase (COX), which has 
two isoforms, COX-1 and COX2. In the peritoneal macrophages of women 
with endometriosis, COX-2 is expressed in greater quantities, whereas in 
severe stage endometriosis COX-1 is expressed. (74) Therefore the 
expression of COX enzyme in the peritoneal macrophages is linked to the 
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concentrations of PGE2 in the peritoneal fluid within the womb of the women 
and also the severity of endometriosis. (74). 
 
 In many cases, there has been a higher expression of COX-2 in ectopic 
endometriotic lesions, with increased production of prostaglandin E2 from 
primary cultured stromal cells in the ectopic endometriotic lesions. (75). In 
contrast, it is also thought that pro-inflammatory cytokines such as tumour 
necrosis factor alpha (TNF-alpha) and interleukin- 1beta (IL-1Beta) can cause 
over-expression of COX-2 in women with endometriosis. (76) The feedback 
loops involving pro-inflammatory cytokines such as IL-1beta and TNF- alpha 
in peritoneal macrophages and prostaglandin E2 can cause the over 
expression of COX-2 in peritoneal macrophages and ectopic endometriotic 
stromal cells in women with endometriosis. (76)  
 
Enzymes such as steroidogenic acute regulatory protein (StAR) and P450 
aromatase (as mentioned earlier) control the steps in the production of 
oestrogen. Prostaglandin E2 plays a role in inducing StAR and aromatase in 
the endometriotic stem cells, which results in the spontaneous production of 
oestrogen. (77). Prostaglandin E2, upon the rise in concentration of peritoneal 
fluid, binds to the G-protein coupled plasma membrane receptors. (77) There 
are 4 different plasma membrane receptors, and binding of PGE2 to Receptor 
2 and 4 will activate adenylyl cyclase and protein kinase A (PKA), causing a 
Ca2+ influx and myometrial contractility. (78).   
 
Therefore, it is important we conducted searches for other important genes 
and molecules through a bioinformatics approach with the aim of linking the 
processes mentioned above to what occurs in endometriosis. 
 
1.5.2.8- Calcium signalling and uterine contractility 
 I also investigated genes and proteins that are important in the calcium-
signalling process within the endometrium and myometrium of women with 
endometriosis. With calcium signalling resulting in contractions of the uterus, 
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there is a possibility according to a study by Bulletti et al that uterine 
contractions may increase the intensity of symptoms in patients with 
endometriosis. (79) In addition, aberrant myometrial contractility may aid 
retrograde menstruation. Therefore proteins or genes found that express 
certain ion channels or transmembrane receptors should be investigated. 
 Myometrial contractility requires phasic influx and efflux of calcium ions 
(Ca2+) across the membrane.  Ca2+ efflux occurs via Ca-ATPase and 
Na+/Ca2+ exchanger. (80) The transmembrane sodium ions (Na+) and Ca 2+ 
work together with the membrane voltage and dictate the direction of Ca2+ 
fluxes. (80) Calcium activated potassium K+ channels (Kca) are also sensitive 
to the flow of Ca2+ ions and the membrane voltage. (80) These channels are 
important in contributing to the resting membrane potential of the smooth 
muscle in the myometrium due to the large conductance and high Ca2+ 
sensitivity. (81) Studies have shown that blocking Kca channels may influence 
the contraction of the myometrium. (81) Ca2+ activated chloride channels 
have also been reported in the myometrium and produce depolarisations and 
the main source of Ca2+ for contraction is entry through voltage-sensitive L-
type Ca channels.  The entry of Ca2+ causes further depolarization of the 
membrane potential.  Entry of Na+ via an agonist-stimulated non-specific 
cation channels will also depolarize the membrane. (81) 
In the myometrium, contractions can occur through inositol triphosphate (IP3) 
receptor mediated release. This occurs via an agonist such as prostaglandin 
or oxytocin binding to receptors on the surface membrane, subsequently 
activating phospholypase C via GTP-binding proteins and hydrolysing the 
phosphatidylinositol 4,5- bisphosphate (PIP2) in the cytosol. This results in the 
production of IP3 and a release of Ca2+ from the sarcoplasmic reticulum 
(SR). (82)   
 In addition to the plasma membrane L-type Ca2+ channels, there is also an 
internal Ca2+ store the sarcoplasmic reticulum (SR).  Its Ca2+ may be 
released into the cytoplasm to augment contractions. (81) The release of 
Ca2+ is mediated by an increase of IP3, which subsequently binds to the 
receptors on the SR membrane. (82) SERCA, which is a P-Family Ca-
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ATPase channel, allows the uptake of calcium ions from the cytoplasm into 
the lumen of the SR via the use of ATP against the Ca gradient. (82) 
SERCA2b is the most abundant of the three isoforms within the smooth 
muscle of the uterus. (81,82) According to a study by S.Wray/A Slunygol, it 
was suggested that there is an increased rate of calcium ion accumulation in 
labouring myometrium as both SERCA2b and SERCA2a were found to be in 
increased expression. Earlier work by Taggart and Wray (1998) also 
suggested that inhibiting SERCA might result in an increase in calcium ion 
movement, therefore an increase force of contraction, as there is an inhibition 
of entry of calcium ions into the sarcoplasmic reticulum. (82) 
1.5.2.9- Altered Immune Response 
 
We also considered the role of the immune system and immune related 
inflammatory mediators that may be raised in patients with endometriosis. 
Genes or molecules that may be involved in an altered immune response in 
patients with endometriosis may help us with understanding the pathology. 
Gilmore et al in 1992 investigated how lymphocytic activity may be different in 
women with endometriosis compared to women who do not have the 
condition. (83) The study found how the proliferation of lymphocytes was 
lower in women with endometriosis compared to controls. (83) 
 
Studies have shown how the peritoneal fluid in women with endometriosis 
usually contains an increase in a number of cytokines. A study by Piva et al in 
2003, showed how an increase in inflammation causes an increase in IL-1, IL-
6, IL-8 and tumor necrosis factor alpha. (84) As well in the proliferative and 
secretory phase of the menstrual cycle, studies such as that by Khan et al in 
2004 have shown there to be an increase in the number of macrophages. (84)  
 
Therefore, the suspected rise in inflammatory mediators may be responsible 
for the other pathways such as proliferation and those mentioned earlier in the 
report. Studying the genes and proteins involved in an altered immune 
response in patients with endometriosis through a bioinformatics approach will 
help us achieve a greater understanding into how the symptoms may arise. 
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1.5.2.10- Embryo Implantation 
 
We also looked at genes and molecules involved in impaired embryo 
implantation in women with endometriosis. With little known about infertility , 
we hoped a bioinformatics approach would help us create a better 
understanding.  Studies, such as that of Burney et al in 2007, investigated 
how there was a down regulation of factors, such as MUC-1 and 
osteopontin, involved in embryo attachment in patients with endometriosis 
compared to normal controls. (85) MUC-1 is a glycosylated phosphoprotein 
that is important in adhesion during implantation. (85) Another study by Arici 
et al in 1996 looked at the effect of endometriosis on implantation. (86) The 
study found that implantation rate (gestational sac per transferred embryo) 
was lower in endometriosis compared to a group with unexplained infertility. 
(86)  
 
Cho et al in 2009 studied the osteopontin mRNA expression in the eutopic 
endometrium of patients with endometriosis. (87) Osteopontin (OPN) has 
important functions in immune responses such as apoptosis and bone 
remodelling, and has been shown to be involved in embryo implantation in 
past studies. (88) Cho et al’s study investigated 79 patients with 
endometriosis and 43 without the condition. (88) In contrast to what was 
found by Burney in 2007, Cho et al found that Osteopontin expression was 
higher in women with endometriosis compared to controls. (88) Unlike 
Burney’s study indicating the down regulation has an effect on implantation, 
Cho suggested the increased expression will have an effect on the 
pathogenesis of the condition and should be used as a diagnostic marker. 
(88) 
The studies outlined the various pathological processes showing a variety of 
genes aberrantly expressed in patients with endometriosis, however there is 
no clear or coherent explanation into why and how endometriosis occurs. 
Theories such as retrograde menstruation, and evidence of linkage to 
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chromosomes 7 and 10 have emerged, however computational technology is 
needed to collate all the data found in different pathological pathways to 
create mapping systems and imaging. Therefore Bioinformatics has allowed 
us to collate the genetic information through various high-technology 
programs, and provide a greater understanding into pathways and find 
particular genes/molecules in these pathway that are affected. Bioinformatics 
provides an opportunity to identify the key players in the pathogenesis of the 
condition, with aim of targeting these particular genes/proteins in future 
therapeutic purposes.  
 
1.6-What is Bioinformatics? 
 
Bioinformatics is a field of scientific research, which merges with computer 
technology, carrying the aim of discovering new insights into a biological 
process or a medical condition. (89) At the start of the “genomic revolution”, 
the importance of bioinformatics grew because a database was needed to 
store biological information such as amino acid and nucleotide sequences. 
(89) It became clear recently that all this information can be combined so a full 
comprehensive picture can be formed into how particular biological pathways 
and cellular activities function and how they may be altered in certain disease 
states, such as endometriosis. Analysis is completed through the 
development of mathematical formulas and statistical information allowing for 
a study of the relationship of large sets of biological and molecular data 
through programs such as Ingenuity IPA. (90)  
 
Mishra et al in 2010 investigated lung cancer through a bioinformatics 
approach, using the Ingenuity IPA Software program. (90) The study involved 
using Ingenuity to investigate the RAS subfamily, which includes a family of 
proteins that cause over-expression of cancer causing genes (M-ras) resulting 
in the formation of a tumor in the lung. (90) Similarly, using information on 
testicular proteins from a protein database, Fu-Jun et al in 2011 performed a 
bioinformatics and Pathway analysis integrating the data into a 
comprehensive functional network (91). The study used the clustering of 
particular testicular proteins, and compared the organization of these clusters 
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to positional clustering of genes on the chromosomes. (91) The biological 
interpretation of testicular functions in a network context provided a greater 
understanding of the physiology. (91) 
Bioinformatics has also been used in studies to calculate the substitution rate 
in genes. (92) The study by Mank et al in 2009 aimed to carry out analysis of 
sex-biased genes and the study used a bioinformatics approach following the 
input of micro-array data, which compared the male and female gene 
expression in different chicken embryo tissues. (92) The study found that from 
the 15982 significantly expressed coding regions assigned to autosomes of 
the Z Chromosome, approximately 18% were sex biased in any one tissue. 
(92) 
 
 Microarray technology used in this and many other studies opens the  
possibility to study expressional patterns, increasing understanding towards 
genomic mechanisms. (92, 93) The principal behind microarray analysis is 
initially the hybridizing of two DNA strands so nucleic acid sequences will pair 
with hydrogen bonds between nucleotide base pairs. In these strands, more 
complementary base pairs in a nucleotide sequence means there is a tighter 
bonding (non covalent) between the two strands. (94) Fluorescently labeled 
target sequences bind to a probe sequence, and expression analysis 
applications such as gene expression profiling, single nucleotide 
polymorphism (SNP) detection and geneID are used to detect DNA/RNA that 
may or may not be translated into a protein. (93) 
 
Eyster et al in 2005 investigated the DNA microarray analysis of gene 
expression markers in endometriosis. (94) The study showed how the 
expression of 8 genes from a total of 4,000 or so genes on the DNA 
microarray was increased in endometriosis implants in patients compared to 
the uterine endometrium of normal women. (94) It also showed how DNA 
microarray analysis is an effective tool for identifying differentially expressed 
genes between uterine and ectopic endometrium. (94) 
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In this research project, we planned to review the data from various other 
studies that have produced targets or specific genes, which are expressed or 
have been identified as being involved in the pathology and aetiology of 
endometriosis. 
With little known into the pathogenesis of endometriosis, bioinformatics was 
used to provide a plausible genetic explanation and understanding into the 
disease. Our aim was to provide a breakthrough into specific genes, proteins 
and transcription factors that are involved in the various biological processes 
that occur in patients with endometriosis and show how they may be 
interlinked. Most investigators feel that endometriosis is inherited in a 
polygenic/multi-factorial mode however the genetics into the condition is still 
complex and largely unknown. (95)  
 
We used tools such as Ingenuity, Genevestigator, Opossum and UniProt as 
part of our bioinformatics approach. These programs are explained in Chapter 
2: Methodology.  
1.7- Transcription and Transcription Factors 
As well as looking at genes that may be responsible for the functioning of 
endometriosis and the processes involved within the condition, we will also be 
investigating factors that control the expression of these particular genes that 
largely depends on the transcription and then translation. (96) Regulation of 
transcription is important in gene expression, and mRNA (messenger RNA) is 
often used as an indication of a gene activation with the assumption that the 
mRNA will be used for a translation of encoded protein in the comparably 
short time window (97).  
We investigated the transcription factors that control the expression of key 
genes involved in endometriosis. Transcription factors are sequence-specific 
DNA-binding factor proteins that are able to bind to DNA sequence during 
transcription, and therefore regulate the flow of genetic information from DNA 
to mRNA. (98) Transcription factors function through promoting or inhibiting 
the recruitment of RNA polymerase to specific genes. (98)(99) Transcription 
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factors possess a DNA binding domain, which is essential in specific 
sequences of DNA binding to them for regulation. (99) 
According to Babu et al, there are 2600 proteins containing DNA-binding 
domains in the human genome and they function as transcription factors. 
(100) Many genes possess several binding sites for unique transcription 
factors, and on some occasions, the expression of these genes require the 
action of many different transcription factors working at once. (99)  
Transcription factors have many functions physiologically.  Many transcription 
factors, such as those involved in ovarian or endometrial cancer are known as 
Oncogenes and Tumour suppressors. They regulate the cell cycle of cancer 
cells. (100) An example of an Oncogene is Myc, which is important in cell 
growth and apoptosis. (101)  
Transcription factors are also important in development of cells within organs, 
and function by turning on or off the transcription of certain genes, allowing 
changes in cellular activities to occur for differentiation within the tissues. 
(101) Lemons et al in 2005 studied how the HOX transcription factor family is 
important in the anatomical development and in cascade systems switching 
on the transcription of other genes.(102) Other transcription factors that are 
important in development are those such as factors encoding the Sex-
Determining Region (SRY) gene. (103) 
In relation to the female reproductive system and its physiology, there are 
many transcription factors that are involved in signalling cascades regulating 
genes involved in endometriosis. If a signal within a cascade requires a gene 
to be up or down regulated in a cell, transcription factors will usually be 
downstream in the cascade. (103) As mentioned earlier, endometriosis is an 
oestrogen-dependent condition, and the signalling requires oestrogen-
receptor transcription factors. (104) After being secreted by the ovary or 
placenta, oestrogen binds to the receptor in the cytoplasm and then will bind 
to the DNA-binding site. (104) It is likely, therefore, that certain transcription 
factors related to the oestrogen signalling cascade will be involved in 
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endometriosis and we will look to investigate those transcription factors 
further.  
During my research (as explained in Chapter 4:Data and Analysis), FOXD3 
was the transcription factor we identified to be the key player in the 
pathogenesis of patients with endometriosis. 
 
 
1.7.1-What is FOXD3? 
FoxD3 is a transcription factor belonging to the fork-head family of 
transcription factors (characterized by a fork-head box domain for binding). 
The transcription factor binds to the sequence 5'-A[AT]T[AG]TTTGTTT-3' and 
acts as a transcriptional activator and repressor.  FOXD3 is known to promote 
development of neural crest cells from neural tube progenitors. (105) They are 
important in promoting the development of neural crest cells, restricting neural 
progenitors cells to the neural crest cells. FOXD3 is important in the 
maintenance of pluripotent cells in the peri and pre implantation stages of 
embryogenesis, which is the process in which the embryo forms and develops 
into the foetus. (105) 
Currently there has been no investigation in human or animal studies of the 
role of FOXD3 in endometriosis. In referring to Chapter 3: Data and Analysis, 
it was found that FOXD3 regulates many genes that are involved in 
endometriosis.  
Therefore in the process of the study described in this thesis, I collated 
available evidence on a variety of cellular functional aberrations associated 
with endometriosis; employed bioinformatics tools to systematically 
investigate the interaction between different cellular biological pathways and 
predicted key players including the transcription factor FOXD3. In a brief 
laboratory experiment I tested the involvement of this Transcription factor in 
patient samples and confirmed its possible involvement in endometriosis. 
Therefore I propose that the use of bioinformatics in this way is a fundamental 
advancement to improve understanding of the pathological process of 
endometriosis and further studies are needed to identify key therapeutic and 
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diagnostic targets with the use of bioinformatics tools before actual studies on 
human subjects. This approach will reduce the need for unnecessary invasive 
procedures on animals and in humans. 
 
Our study was able to identify the common genes, proteins and transcription 
factors, which were key players in processes such as apoptosis, calcium 
signalling, proliferation and senescence of the endometrium. Our main finding 
has been experimentally validated and suggests differential role of FoxD3 and 
the associated transcription factors in endometriosis. We were able to confirm 
the presence of the main transcription factor FOXD3 in endometrial samples 
of normal fertile control patients, and examine if aberrant expression of 
FOXD3 (and the genes its regulates) in patients with endometriosis was able 
to correspond to our bioinformatics findings. 
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CHAPTER 2 
2- BIOINFORMATICS METHODOLOGY 
From what was discussed in the introduction, a bioinformatics approach was 
used to investigate the genes and proteins involved in the pathological 
processes within endometriosis, and how they may be inter-linked with each 
other. 
 
Bioinformatics is a field of molecular and genetic biology that is being brought 
to the forefront of today’s scientific research. An increasing amount of 
research projects today have integrated bioinformatics and microarray studies 
into their work when investigating various conditions and biological pathways. 
 
When PubMed was used and the keywords “bioinformatics endometriosis” 
was inserted, the search returned with 41 related studies. Numerous studies 
in this search investigated various biomarkers, which are used as diagnostic 
tests for patients with endometriosis. For example, Tokushige et al used 
bioinformatics to study the proteins that were found in urine of endometriosis 
patients. (106) In a similar way to Tokushige et al in his study, Ferrero et al 
used 2-D gel electrophoresis and a bioinformatics approach to carry out a 
proteomic analysis of the peritoneal fluid of women in endometriosis. (107) 
However, these studies and 2 others identified in the literature search do not 
provide a genetic explanation into the pathology and aetiology of 
endometriosis comprehensively. In contrast, our study identifies the common 
biological processes associated with endometriosis. We will also identify 
common genes and transcription factors that are affected in patients with 
endometriosis. 
 
Rai et al in 2010 used bioinformatics to study the proteome profiling of the 
endometrium in women with endometriosis. (108) Proteomics (study of 
proteins) were used to compare protein expression in the endometrium of 
patients with endometriosis to normal fertile control patients. The study was 
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successful in identifying genes, which were responsible for endometriosis. 
(108) Rai et al identified the dysregulation of more than 70 proteins in the 
proliferative phase of eutopic endometrium in stage 4 of endometriosis and 
secretory phase of stages 2,3 and 4 endometriosis.  The study found other 
key genes that were up regulated in patients, such as DJ-1, HSP27, HSP60, 
HSP70, GRP78, HSP90 beta, and MVP. (11) In using a bioinformatics 
approach to identify the proteomic changes in the endometrium of women 
with endometriosis, the study failed to identify how related common biological 
processes and pathways may be affected.  
 
Our study was able to identify the common genes, proteins and transcription 
factors, which were key players in processes such as apoptosis, calcium 
signalling, proliferation and senescence of the endometrium. Our study 
progressed further and used laboratory techniques to examine how the 
common transcription factors (involved in regulating common key-genes) are 
affected in patients with endometriosis.  
 
2.1- Endometriosis Genetic data mining 
 In order to collate the genes and proteins that may be linked to the various 
pathological processes occurring in endometriosis, we carried out 
comprehensive PubMed searches for journals that have studied such 
processes.  
 
To gain an initial understanding, we conducted a search using the keywords 
“Endometriosis bioinformatics” and “Endometriosis microarray studies”. This 
helped us view the common genes that are expressed in patients with 
endometriosis. The studies also provided us an insight into genes and 
proteins that have been investigated as being possible diagnostic markers in 
patients, or genes that are up/down regulated upon treatment in patients. We 
then progressed to conducting separate searches of different biological or 
pathological processes involved in endometriosis. Each search was 
completed separately to find and review journals, which contained information 
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on genes and proteins implemented in the disease. The specific searches 
conducted provided specificity to our genetic and molecular data we collated 
allowing for organization when we inputted them into various computational 
software. 
 
Therefore, as discussed in the introduction, it is important different keywords 
were inputted into PubMed to investigate each pathological process. 
 
Endometriosis microarray studies- returned with 67 studies 
Senescence Endometriosis- returned with 4082 studies 
Proliferation Endometriosis- returned with 545 studies 
Oestrogen responsiveness Endometriosis- returned with 27 studies 
Embryo Implantation Endometriosis- returned with 224 studies 
Embryo implantation in Endometrium (CONTROL SEARCH)- returned with 
2838 studies 
Inflammation Endometriosis- returned with 422 studies 
Altered Immune Response Endometriosis- returned with 17 studies 
Retrograde Menstruation Endometriosis- returned with 1080 studies 
Metastasis Endometriosis- returned with 266 studies 
Calcium signalling Endometriosis- returned with 2 studies 
Progesterone Endometriosis- returned with 1175 studies 
Prostaglandins Endometriosis- returned with 197 studies 
P450 Endometriosis- returned with 57 studies 
Apoptosis Endometriosis- returned with 243 studies. 
 
We used the keywords “embryo implantation in the endometrium” to compare 
the difference in gene expression in the process of implantation in the normal 
endometrium to that of patients in endometriosis, if it was found that any 
genes would be aberrantly expressed.  
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There have been many studies, such as Salamonsen et al in 2002 that have 
shown molecules such as calbindin-D9k, a regulator of calcium, to be up 
regulated by progesterone and increased in the uterus during early 
pregnancy. (109) Also other cytokines such as MNSFbeta were shown to 
have a lower expression in implantation sites on day 4 and 5 of pregnancy 
upon the embryo attaching in endometriosis patients. (6) A selection of many 
other molecules such as hsa-miR-101, hsa-miR-144, and hsa-miR-199a have 
been shown in studies such as that by Chakrabarty et al in 2007 to target the 
COX-2 gene, which was involved in peri and pre-implantation of the embryo in 
mice studies. (110)  
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2.2-Overview of Gene/Protein selection from the Literature 
 
 
 
 
 
 
 
                                
 
 
 
 
 
 
 
 
 
   
 
 
 
Inserted relevant keywords into 
PubMed 
Genes/molecules that were altered in patients with endometriosis (up or down regulated) 
selected     ( in-vitro / in-vivo studies on humans /animals) 
 
Set inclusion/exclusion criteria of what genetic/protein information should be used to 
ensure the reliability and validity of our data 
Further scrutiny / critical review of individual relevant articles and studies adhering to our 
preset inclusion/exclusion criteria 
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2.2.1- Inclusion/Exclusion criteria of genetic selection 
 
We looked to select genes/molecules from research articles that have 
conducted in-vitro and in-vivo experimental work when investigating 
expression profiling in patients with endometriosis. We excluded 
genes/molecules expressed in endometriosis according to review articles 
because no individual lab work was conducted in these studies, so reliability 
of the data could be questioned.  
 
We reviewed studies that conducted work on both animal and human 
specimens. Studies were also included that had been conducted in vitro. An 
in-vitro study refers to one that is conducted on an organism that has been 
isolated from their biological context. (111)  
 
Genes/Proteins etc were plotted onto an Excel Spreadsheet 
 
 
Insertion of the Genes/Proteins/etc into Ingenuity IPA Software 
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The advantage of using studies that have conducted in-vitro work is that 
investigators have been able to obtain data from living organisms in which 
biological pathways and processes are fully functional. (111) We were able to 
obtain details on genes/molecules that have been investigated in various 
interactions, pathways and processes in a living organism. Common studies 
often include cells derived from multicellular organisms such as a cell or 
tissue culture or purified molecules in a test tube. (2) Examples include 
Polymerase Chain reaction, in-vitro fertilization and protein purification.  
 
We critically reviewed each article to ensure any genetic/molecular marker we 
used from the study possessed reliability and validity. We ensured each study 
was conducted in the past 10 years and preferably no later. With advances in 
technology, findings related to endometriosis may be different now compared 
to 20 years ago, even though still little is known regarding the pathogenesis 
and etiology of the disease currently. We also made sure the study was 
conducted in a suitable institute such as in a University department or in an 
Obstetrics and Gynecology department of a hospital. The setting of a study 
displays up-to-date technology and laboratory equipment is used, as well as 
appropriate samples for the study (samples from patients with endometriosis 
and relevant controls).  
 
We also ensured the study had obtained its genetic data from a sufficient 
sample size.  There are many studies that have conducted in-vitro studies on 
small sample sizes, such as a small patient group (less than 10 patients). This 
presents an issue of the data not being of credible nature. It was also 
important for the study to indicate where the samples had been collected from 
and how they had been collected before they were studied in an in-vitro 
manner. Noting that the samples had been collected from hysterectomies, 
endometrial pipelle procedures or obtaining cells from peritoneal fluids from 
patients are some examples of suitable procedures. 
 
It was also important for us to be aware asto how the patients for sample 
collection had been selected. For much of our search categories, such as 
calcium signaling, proliferative activity in patients with endometriosis and 
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others, different unrelated conditions can affect the genes and proteins related 
to the these pathological and biological processes that were searched. 
Therefore, it was important the studies had used samples in which the 
patients had no other conditions or were taking no medication at the time. It 
was also important that the studies used samples from patients who weren’t 
pregnant or had not had past recurrent miscarriages. Studies had to use 
samples collected from patients of the same age and demographic groups.  
 
We obtained genes and proteins expressed in the various biological and 
pathological processes of interest in only patients with endometriosis. From 
the different studies, these genes and proteins were compiled into a table 
under the different categories. We also looked for names of important 
receptors that were involved in the processes of interest (e.g receptors 
involved in calcium signaling, proliferation etc). 
  
The tables of genes/molecules were then managed in the following manner 
using the appropriate programs. These programs were helpful in providing 
any link between genes/molecules/proteins differentially expressed at the 
different biological processes, and also identifying the regulation or pattern of 
expression of these particular genes. 
 
2.2.2- Data Mining Output  
Below is an example of a list of genes that was formulated from one of the 
keyword searches we inputted as part of our Data mining search on 
“Proliferation Endometriosis”. This data was found from the study to be 
relevant to endometriosis during the proliferative activity in the endometrium. 
 
15-
PGDH 5-LO MCP1 IL-6 BRCA1 FKBP52 
FR 
167653 
PPAR-
bp PAR1 
COX-
2 
TLR-
4 COL4A2 PGE2 BRCA2 IL-10 HLA-G GRO1 PPACK 
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IL-8 
NF-
κB COL5A2 
S100-
A8 GnRH CCL21 MCP-1 GRO2 ALDH 
 
 
 
2,3-  Overview Bioinformatics Management of Data 
 
START 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Core Genes/Proteins 
were inputted into 
Genevestigator. 
Those found to be up 
regulated were inputted 
into Opossum to reveal any 
common transcription 
factors for the genes.  
  
Transcription factors were 
inputted into UniProt to 
find there other aliases.  
The obtained gene lists 
were combined with the 
inputted gene lists in 
Ingenuity to confirm a 
connection 
Mined data inputted into 
Ingenuity.  
Once transcription 
factors were confirmed 
of being linked to 
relevant genes, 
Immunohistochemistry 
conducted to validate 
findings. 
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2.3.1- The use of Ingenuity IPA Software 
 
Ingenuity IPA is a software program, which allows research projects to 
analyze and gain an understanding of biological pathways in science. IPA 
integrates data from different experiments to provide insights into biological 
and chemical interaction in common pathways as well as the progression of a 
disease in these canonical pathways and other systems. IPA is an important 
tool for drug discovery as well as gene and protein discovery. Founded in 
1998, Ingenuity is an important driving force for a bioinformatics approach in 
the scientific research world. The ability of the program to visualize, explore 
and analyze biological experimental data allows insightful work for 
researchers part of the pharmaceutical and academic institutes. 
The program allows efficient analysis and interpretation of genomic and 
proteomic datasets for profiling, which helps many researchers and 
organizations identify therapeutic targets and connection.  The program also 
provides an understanding into the toxicity of a drug, as well as identifying 
important biomarkers through gene expression and proteomic array studies.  
INPUT OF DATA MINING GENES AND MOLECULES FROM LITERATURE 
SEARCH 
Figure 2.3.1.1 (found at the end of this chapter with corresponding figures 
from this chapter) is an example of the input of genes and molecules found 
from the above literature search on “proliferation endometriosis” into 
Ingenuity. Ingenuity was able to translate the inputted raw data and provide 
the full names of genes and proteins in this figure, as well as the location in 
the cell. 
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OUTPUT 
Figure 2.3.1.2 shows how Ingenuity IPA instantly translated the data 
spreadsheet and provided a list of genes that are differentially expressed in 
endometriosis from an illustrated interlinked map of figures involved in 
proliferation. This was accessed from Data Analysis>Networks>Merge all 
available networks>Overlay functions>Functions and Diseases> Reproductive 
System Disorder 
The next stage was to input this data into Genevestigator to investigate, which 
genes were up regulated and which were down regulated. 
2.3.2-The Use of Genevestigator V3 
Genevestigator is a software program, which shows genes that are up 
regulated and down regulated in certain conditions. Genevestigator V3 
provides a meta-analysis of gene expression across a collection of 
experimental microarray data. (112) The Meta analysis provides a 
confirmation of our findings from Ingenuity, and greater insight into the 
activities of specific genes from the list expressed in endometriosis. (112) 
Through a Hierarchical Clustering, the tool allows the group of genes with 
similar profiles across arrays to be clustered and shown to be up/down 
regulated in conditions or various anatomical parts of the human body.  
INPUT OF GENETIC/MOLECULAR INFORMATION 
Below is a list of genes involved in proliferation of the endometrium 
differentially expressed within the endometriosis according to Ingenuity. 
  
BCL2  SMAD6 
CYP19A1 CCR1 
IL8 FPR2 
ROCK2 NRSA1 
BRCA1 CDK1 
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DYNLL1 GREM1 
NFKB1 PIK3R1 
 
We would input these into the Meta analyses program to find which were up 
regulated in endometriosis. Figure 2.3.2.1 shows the initial screen in which 
raw data is inputted. The array selection for the genes to be analyzed was 
from Human Genome studies only (as opposed to mouse or animal studies).  
 
OUTPUT OF GENES UPREGULATED IN ENDOMETRIOSIS 
Those genes coded indicated in red in Figure 2.3.2.2 were be up regulated 
according to the meta-analysis.  
It was found BCL2, IL8 AND SMAD6 were up regulated. 
The next step would be to input these 3 up-regulated genes into Opossum to 
discover which is the common regulatory transcription factor. 
2.3.3- The Use of Opossum 
Opossum is a web-based program useful for detecting transcription factor 
binding sites in sets of co-expressed genes. Opossum is an important system 
that searches for evidence of co-regulation of genes (or a group of genes) by 
a common transcription factor. The program also identifies, through a pre-
combined computated database, conserved transcription factor binding sites 
of these transcription factors for the genes that are regulated. (113) Opossum 
has been important in providing identification of common transcription factors 
in human studies, as previous work on human genomic regulatory studies 
were ineffective.  
INPUT OF UPREGULATED GENES INTO OPOSSUM 
The web-based program is used from the input of the genes of interest into 
the site as shown in Figure 2.3.3.1.  Human studies are then selected, as well 
as the option of ‘HUGO/MGI Symbol/Alias’ for the GeneID type. Taxonomic 
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super groups can also be selected (plant, human or insects) as well as the 
amount of upstream/downstream sequences the program wishes to produce. 
We selected 2000/0 on the upstream/downstream score to provide a concise 
enough list of relevant transcription factors regulating the genes as close to 
the promoter region as possible. The selection criteria can be seen in the 
screen shot above.  
The ordering of transcription factors produced was sorted by a Z-Score. The 
electronic Z score expresses the divergence of the value so the larger the Z 
score, the less probable the result will be due to chance.  
OUTPUT OF DESIRED TRANSCRIPTION FACTORS 
From the group of transcription factors, it was found ZNF354C to be the 
transcription factor which had the most background hits and most binding 
sites for genes related to proliferation that were up regulated in endometriosis 
which we inputted. The final stage would have been to use UniProt to find any 
alternative names for this transcription factor. As can be seen in Chapter 3: 
Data and Analysis Chapter, FOXD3 was the most common transcription factor 
found to regulate a majority of the genes found up regulated in endometriosis. 
Therefore, the final step was to input FOXD3 into UniProt. 
2.3.4- The Use of UNIPROT 
UniProt is a web search based program that uses various databases to 
provide different sequence names for one specific protein/molecule inputted. 
The databases used are Uni Prot Knowledgebase, UniProt Reference 
Clusters and UniProt Archive. The program is also used for aligning protein 
sequences together as well as identifying proteins in a specific sequence put 
into the program.  
Figure 2.3.4.1 shows how UniProt was used. With FOXD3 (well-known 
transcription factor) being inputted into the Protein Knowledgebase, the 
search returned with 11 different other accessions of the transcription factor 
FOXD3. From here, we used FOXD3 and its human accessions and put this 
back into Ingenuity with the respective genes that it regulates.  
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Immunohistochemistry (IHC) was used to validate our bioinformatics findings 
as seen in Chapter 3: Data and Analysis. We were able to confirm the 
presence of the main transcription factor FOXD3 in endometrial samples of 
normal fertile control patients, and examine if the aberrant expression of 
FOXD3 (and the genes its regulates) in patients with endometriosis was able 
to correspond to our bioinformatics findings. 
2.4-IMMUNOHISTOCHEMISTRY (IHC) METHODOLOGY 
 
Immunohistochemistry Introduction 
  
Immunohistochemistry is an important procedure for detecting the expression 
of particular antigens in a tissue or cell by observing the binding of antibodies 
to the targeted antigens. (114)  
 
The procedure is important in research such as this, in visualizing how 
biomarkers and specific proteins may be localized and distributed in certain 
tissues at a cellular level. (114) It is useful for the diagnosis of abnormal 
(cancer cells) in patients through a clinical setting. An antibody-antigen 
interaction can be visualized a number of different ways, including the 
antibody being conjugated to an enzyme such as peroxidase or the antibody 
being tagged to a fluorophore which allows immunofluorescence detection. 
(115) 
An antibody (Ig) is a glycoprotein used by the immune system to identify 
foreign substances such as bacteria and viruses (antigens) and neutralize 
them. (114) There are five classes of antibodies: IgG, IgA, IgM, IgE and IgD.  
In Immunoassays, IgG and IgM are important, Ig G, the most abundant 
antibody, is produced by B Lymphocytes and provides antibody-based 
immunity against antigens. The classical “Y” shape of the IgG molecule (MW 
~150 kD) is composed of four polypeptide chains — two light chains (each 
with a molecular weight of ~25 kD), and two heavy chains (each with a 
molecular weight of ~50 kD) connected with a disulphide bond. (114) Each 
end of the Y portion of antibody is called the Fab region (fragment antigen 
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binding region). The Fab and Fc regions are useful in immunoassays, with 
antibodies being labelled in the Fc region during immunohistochemistry. (114) 
Antibodies used for detection may be either polyclonal or monoclonal 
antibodies. In our laboratory experiments, we used both in the staining runs. 
Polyclonal antibodies are those produced by immunizing animals such as 
rabbits. The serum contains antibodies derived from different types of immune 
cells and hence is known as polyclonal. (116) Rabbit polyclonal antibodies to 
Foxd3 were used in our experiment. 
 
Monoclonal antibodies are those produced from a clone (single cell line). 
Replicable Tumor cells are fused with immunized mammal cells, such as that 
of a mouse, which produce antibodies.  (116)  
 
Polyclonal antibodies are effective, such as Rabbit IgG, in having the affinity 
to bind to numerous antigen receptors. Therefore FOXD3 was raised in the 
polyclonal antibody as it interacts with many different epitopes (of various 
genes/proteins). Monoclonal antibodies show specificity for a single epitope, 
therefore displaying a greater specificity than polyclonal antibodies. Therefore, 
this is the reason we used Progesterone and androgen receptors raised from 
mouse.  
In order to visualize the localization of the antibody binding, an appropriately 
labeled secondary antibody is used in conjunction with the primary antibody. 
For example, if the primary antibody was raised in the mouse, an anti-mouse 
secondary antibody will be used, and if the primary antibody is raised in a 
rabbit, the secondary antibody will be anti-rabbit.  In our lab work, the 
polyclonal rabbit IgG was used as a primary antibody and the secondary 
antibody used was the ImmPRESS Anti-Rabbit Ig (peroxidase) Polymer. The 
ImmPRESS Anti-Mouse Ig (peroxidase) polymer was used as a secondary 
antibody when the primary antibody was mouse IgG being in the staining of 
Androgen and Progesterone receptor in endometrial cells. The peroxidase is 
a rapid and stable enzyme and the HRP conjugate is an affinity-based 
antibody and reacts with the light and heavy chains of the rabbit IgG or mouse 
IgG.  
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The secondary antibody was specific therefore to the primary antibody. This 
method is known as an indirect immunostaining method and is more specific 
to a direct staining method (only primary antibody binding to the antigen) as 
the signal is amplified. (116) The signal for staining is amplified as numerous 
secondary antibodies binds to the primary antibody through the Fab and Fc 
fragments. (116) 
 
 
An image showing the Illustration of antibody-antigen interaction during 
immunohistochemistry. 
 
 
 
Above is an illustration of how the antibody and antigen interact. As 
mentioned before, the primary antibody (for example the FOXD3 raised in 
rabbit) binds via its Fab and Fc fragments to the epitope of the antigen. The 
secondary antibody will bind to the primary antibody and the substrate stain 
(illustrated as a blue circle) would bind to the secondary antibody allowing for 
visibility microscopically.  
During the immunohistochemistry, in both staining of the FOXD3 and 
Progesterone Receptor and Androgen Receptor, we used tissue from the 
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endometrium of women with recurrent miscarriages, and the placenta as a 
positive control. Both were known to stain upon the addition of both 
antibodies. 
As a comparison to looking at the FOXD3 staining (primary polyclonal 
antibody raised in rabbit) in our samples, we also used normal polyclonal 
rabbit IgG on the samples, to ensure specificity of the staining. A negative 
staining was expected from normal rabbit IgG antibodies on the sample cells 
and therefore acted as a negative control.  
Similarly, when looking at the staining of Progesterone and Androgen 
receptors in our samples, which were both raised in mouse, normal 
monoclonal mouse IgG was added to the samples again to show specificity.  
 
Other control measures that were taken were using a serum blocker when we 
used the polyclonal rabbit IgG antibody. This was added after the primary 
antibody had been added to the slide. Serum blocker ensures all epitopes on 
the tissue sample were blocked to prevent any nonspecific binding of the 
antibody, improving sensitivity of the assay. (116)  
 
2.4.1- The use of IHC to detect FOXD3 
 
Our findings from the bioinformatics study had shown how the transcription 
factor FoxD3 was the key factor involved in regulating the expression of up 
regulated genes involved in the pathology of endometriosis. We subsequently 
tested the hypothesis we generated from our bioinformatics research, and 
conducted immunohistochemistry experiments to observe the interaction 
between FOXD3 antibodies and genes that are expressed in endometriosis. 
We also observed microscopically the interactions of progesterone and 
androgen receptor antibodies and genes expressed in patients with 
endometriosis. This was based on our bioinformatics research in which we 
found genes related to progesterone and androgen receptors being 
expressed in endometriosis according to Ingenuity and Genevestigator. It was 
also found that FOXD3 regulated genes involved in the expression of 
progesterone and androgen receptors such as estrogen receptors. 
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For our immunohistochemistry work, we used 20 patient samples in total 
(n=20), with 10 patients having active peritoneal endometriosis and 10 normal 
fertile control patients. 
 
 
 
2.4.2- Ethical Approval 
 
A literature review was previously performed to ensure any work conducted in 
this study provides novel scientific information. Ethical approval was obtained 
for the study from the Liverpool Regional Ethics Committee (LREC) 
(09/H1005/55) and patients were recruited at the Liverpool Womens Hospital. 
All participants included had given informed written consent. 
 
2.4.3- Selection of Patient Samples 
 
All patients were consented in a confidential manner, having being briefed on 
the purposes of the use the samples for the research during the consenting.  
Biopsies were taken from fertile control groups and an endometriosis group.  
Endometrial biopsies were collected at the luteal and follicular phase of the 
menstrual cycle. The follicular phase (proliferative phase) is the phase in the 
menstrual cycle where the ovaries mature.  Rising oestrogen production 
during the follicular phase allows for growth of the endometrium in the uterus, 
and progesterone receptors are produced in endometrial cells so the 
endometrium is ready for the rising progesterone level during the luteal phase. 
The luteal phase (or the secretory phase) is the later phase of the menstrual 
cycle. Progesterone is produced in this phase, and is important in making the 
endometrium receptive to the implantation of the blastocyst (window of 
implantation). 
The samples used in our experiments were endometrial pipelle and Full 
thickness samples collected from the patients.  Pipelle samples are those 
collected from endometrial biopsies and only contain the functional layer, 
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whereas full thickness endometrial samples possessed the basal and 
functional layer of the endometrium. Full thickness samples are those cut from 
the endometrium of the uterus surgically removed from the patient during a 
hysterectomy. 11 samples out of the 20 collected were full thickness 
specimens.  
 
2.4.4- Inclusion/Exclusion Criteria of Patients Selected 
 
Reproductive women with regular menstrual periods were included in the 
study. Patients seen to have had taken regular medication, been on hormonal 
treatment or breast-feeding in the past 3 months were excluded from the 
study. Also, patients with an intrauterine or Mirena device were excluded, as 
well as those patients who have had a regular miscarriage or any recent 
diagnosis of cancer. Those who had exhibited abnormal bleeding, or have 
displayed symptoms for any other unrelated condition were excluded.  
Patients were included in the endometriosis study group provided they have 
had active peritoneal endometrial and complained of major symptoms (these 
symptoms being listed in the Chapter 1: Introduction). 
Normal fertile patients must have had at least 1 pregnancy and must not have 
had any endometrial pathology or symptoms related to endometriosis such as 
pelvic pain. All normal women must have had their pelvis assessed. This is be 
done through an investigative procedure known as a laparoscopy. (25)  
 
Sample Processing / Tissue sectioning 
 
Once collected, the samples were stored in NBF formalin at room 
temperature. The tissue samples for experimental work were then embedded 
onto wax blocks, cut and appropriately coated. They were labelled with the 
specimen ID, date of the staining as well the details of the antibody employed 
for that slide (FOXD3 1in X) 
 
2.4.5- Immunohistochemistry procedure 
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De-waxing of the sample 
The prepared sectioned slides were submerged into xylene and differing 
concentrations of ethanol to completely dewax the samples on the slides in 
the rack.  
 
Antigen retrieval stage of the samples 
A heated 10mM citrate buffer solution was prepared, in which the slides were 
submerged in for 1 minute to break protein bonds and reveal antigenic sites 
for antibody interaction. (114)  
The slides were then placed into a 0.3% dilution of hydrogen peroxide (H202) 
in TBS solution for 10 minutes. The area of interest on the slide was then 
circled with hydrophobic pen marker. 
 
Addition of antibodies to the sample 
50microlitres of the respective antibody was added to each section. Following 
this, a drop of the respective secondary antibody was added (explained earlier 
in chapter). Below is a table of concentrations used in each of the staining 
runs we completed. 
Antibody Concentration Source Incubation period 
FOXD3 
(Polyclonal 
antibody in rabbit) 
 
1:800 BioLegend Ltd After addition of 
antibody & serum 
blocker, left 
overnight at 4 
degrees 
centigrade to 
ensure optimum 
interaction. 
Rabbit IgG (rIgG) 1:4000 BioLegend Ltd  
Progesterone 
Receptor (PR) 
(Monoclonal 
antibody raised in 
mouse) 
1:100 BioLegend Ltd After addition of 
antibody, PR, AR 
and MIgG slides 
left for 30 minutes 
room 
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 temperatures to 
ensure optimum 
interaction 
Androgen 
Receptor (PR)  
(Monoclonal 
antibody raised in 
mouse) 
1:50 BioLegend Ltd  
Mouse IgG 
(mIgG) 
1:4000 BioLegend Ltd  
 
Addition of substrate staining 
After the addition of the secondary antibody, a drop of the substrate DAB 
solution (brown deposits to the cell) were added to each slide and left at room 
temperature for 10 minutes. Following this, the slide rack was dipped in 
Haematoxylin, a counterstain used to stain the nucleus blue, allowing for the 
antibody-antigen interactions to be analyzed.  
 
Dehydration of Slides 
After the slides had been dipped in acid alcohol and placed under running 
water to cease substrate reaction, they were dehydrated with differing 
concentrations of ethanol and xylene. This allowed for the slides to then be 
mounted and analyzed microscopically.  
The intensity staining shown on the slides was subsequently analyzed from 
microscopically scoring each slide, and inputting the data into the statistical 
program SPSS. The data and analysis of the bioinformatics findings being 
validated through IHC work can be seen in the next chapter. 
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CHAPTER 2 FIGURES  
FIGURE 2.3.1.1 
 
 
 
FIGURE 2.3.1.2 
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FIGURE 2.3.2.1 
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FIGURE 2.3.2.2 
 
 
 
 
 
 
 
 
 
FIGURE 2.3.3.1 
 
 
 64 
 
 
 
 
 
 
 
 
 
 65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.3.4.1 
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CHAPTER 3- DATA AND ANALYSIS 
3.1 BIOINFORMATICS DATA 
 
STEP 1 
Selection of Raw Data inputted into Ingenuity IPA. 
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Table 3.1- A LIST OF ALL GENES/PROTEINS/MOLECULES RELATED TO 
ENDOMETRIOSIS INPUTTED INTO INGENUITY 
 
 
 
 
 
 
 
TABLE 3.2:   A LIST OF GENES/MOLECULES/PROTEINS RELATED TO 
PROLIFERATION IN ENDOMETRIOSIS INPUTTED INTO INGENUITY 
 
 
 
MAOB  Bcl2  BTRC  CFL1  WT1  RB1  SP1  IDO1  MMP2 
 
Q6PFW1 
 MEG3  bcl2l13  C3  CFL1  P19544  RGS12  Sp110  IFNA1  MMP3  O43314 
 MIF  BIRC3  c7orf23  Cks1  Q06250  RhoA  SPARC  IFNAR1  MMP9  PRDX6 
 MIR21  BMI1  CBARA1  CLIC1  Q9ULE0  RNH1  spp1  IGF1  MRC1  PRDX6 
 mki67  BMP7  CCL1  COMT  Q9GZV5  SOX15  ERBB4  IGFBP6  MUC16  PROK1 
 MME  Dak  CCL2  CRH  Q6GPH4  SOX2  F2R  IHH  muc3  PSAP 
 VCAN  DEFA1  CCL20  CRHr1  P98170  DICER1  FAM38A  IL15  MYH7B  PTEN 
 P18206 
 
DEFB125  CCL20  CSN3  XIAP  DIO2  FASLG  IL17A NANOG 
 
PTGER3 
 Q96JH7  DFFA  CCL5  Cthrc1 TGFB1I1  DKK1  FCGR3A  IL18  NCAM1  PTGES 
 VEGFA  Q9BT76  CCL5  CXCL1 TGFBR2  DNMT1  FGF9  IL1  NFKB1  PTGS2 
 VEGFC  Q8TCY9  CCNE  CXCL14  TNFa 
 
DNMT3a  VEGFD  IL1R1  C7orf3  PTPN22 
 Q96I51  O75445  CCNE2  CXCL14  Tnfrsf1a 
 
DNMT3b  fkbp4  IL8  NOS3  Ptpn22 
 Acta2  O60763  CCR1  CXCR4 
 
SERPINA3  DPPA2  Q6ZQN3  JUN  NOX1 
 
A8MTW9 
 ADPRHL1 UTF1  CCR6 
 
CYP19A1  SF1  DUSP1  FOXO1A  KCNK2  nPR2  LTF 
 AGR2  UTF1  CD163  CYP1B1  SFRP4  E2F1  FRAT1  Kcnma1  NR2F1  MAOA 
 AhR  Q9UBK9  CD36 
 
CYP26A1  SFTPA1  EGFR  GDF3  Q69YN4  ntrk2 ROCK1 
 AKR1B1  P23763  CD44  CYR61  Skp2  Egfr  GRAP 
 
KIR2DL2  otx1  S100A1 
 AKT1  P51809  CD55  PSCDBP  Q05940  EGFR  H2AX 
 
KIR2DS5  OT  S100A4 
 AW320017  Q99536  Cdh1  O75717  STAT  EHD2  HNF1b 
 
KIR2DS4  OXTR  S100A8 
 
ARHGAP20  Q9UIW0  cdk5  O75083  SOD2  eif3a  HOXA10  GPR54  PAPPA  S100P 
 Arnt  TAGLN  CDK6  Q64LD2  SOX1  ELANE  HOXA11  KLF4  PBK  SALL4 
 ATM  TCF7L2 
 
CDKN2BAS  Q9H7D7 THEG  ERK  HRAS  KLF9  PDCD4  SALL4 
 ATP2A2  TCL1a  TERT  P57081  TWIST1  ERAS 
 
HSD17B2  LAMA5  PGD  SERBP1 
 ATP2C1 TGM2  TGFb  P61964  TXNIP  ERBB2  hspa1a  LAMB1 
 
BB114106 
 
 Bax  TLR2  ubl3  Q6PJI9 StAR  ERBB3  HTRA1  Q86TA4  pls3  
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Raf-1 7TM HB24 
B-raf c-Fos CD147 
ROCK-II fkbp52 GREM-1 
sst1 cdc2 LXA4 
sst2 IL-8 BLT1 
NFKB1 FAK BLT2 
PELP1 ARNT MCP-1 
SICA2 TDGF1 PAR1 
CCL14 SPINT1 PPACK 
ALDH FoxM1B CYP19 
ALDH10 FOLR1 p27kip1 
VEGF-A GPR30 RASK 
IGF-1 NR5A1 bcl-2 
  DLX4 
   
 
TABLE 3.3- A LIST OF GENES/MOLECULES/PROTEINS RELATED 
SENESCENCE IN ENDOMETRIOSIS INPUTTED IN INGENUITY 
 
ARNT CD36 flt-1 GSPT1 FBLN1 
AhR MSH2 KDR NKR1 DLX5 
HSD17B1 Hic-5 AhRR G1057D HSD11B2 
TNFR2 RCAS1 KIR2DS5 hMSH2 RHOE 
TNFA CYP19 SOX-2 SLPI p21waf1 
hMLH1 CYP1A1 stmn1-b ENDO-1 MMP1 
PTEN TIMP-2 IL-18 SHBG MMP3 
Pal-1 CYR61 CXCR8 AR gas6 
plk1 EST CFL1 TRKB IL-4 
MMAC1 STS CDKN2BAS CD94 IAP 
NKG2A JAZF1 P450Arom NKG2A GSTT1 
 IGFBP5 KRAS NFKB1 WTN7A GALT 
PIM2 TNPR TBP-2 EMX2 APOA2 
RPL41 GSTM1 IL-6 CCL21 p16Ink4 
     
     
     
 
 
TABLE 3.4- A LIST OF GENES/MOLECULES/PROTEIN RELATED TO 
IMPLANTATION IN ENDOMETRIOSIS INPUTTED INTO INGENUITY 
 
alox1 EGF HTRA1 PROK1 STAT5 
APOA1 FOXO1 LOXL1 SERPINA3  
BMP2 GDA MUC1 SFRP4  
CD44 HOXA10 NR2F2 SPARC  
CD74 HOXA11 PAPPA OPN  
TABLE 3.5- A LIST OF GENES/MOLECULES/PROTEINS RELATED TO 
IMPLANTATION IN THE ENDOMETRIUM INPUTTED INTO INGENUITY 
 
 
Bmp2  Dll4  HOXA10 
 BMP7  EMP2  HPSE2 
 CD44  FGF7  IGF2 
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 CD52  foxa2  IGFBP1 
 CFLAR  FUT7  IGFBP3 
 CHMP1A  GLI1  IHH 
 CSF2  GLI2  IL11 
 CXCL1  GPR30  IRF1 
 cyp26a1  GPER  iTGA3 
 DEDD  H19  MMP3 
 DKK1  HIF1A  MUC1 
 Dkk2  SPP1  NDRG1 
 PTCH1  STAT3  PCK2 
 RXFP1  STC1  PACE4 
 RXFP2  TEAD4  PRL 
 S100A13  Tead4  PROK1 
 S100A4  TM4SF4  LEF1 
 ITGA5  TRPV6  LOXL1 
 ITGB3  MET  SFRP1 
 ITGB4  MMP10  sFRP4 
 BTEB1  MMP2  GLUT1 
 LAMA1  s100G LAMB3 
 
 
TABLE 3.6- A LIST OF GENES/MOLECULES/PROTEIN RELATED TO 
OESTROGEN RESPONSIVENESS AND ENDOMETRIOSIS INPUTTED 
INTO INGENUITY 
 
 
BMP2  CYP19  ESR2  IL1R2 
 CCL11  CYR61  FHL2  IL1R2 
 CCR9  CYR61  GSTM1  JUND 
 cdc2  DKK1 HSD17B1 
MMP3 
 
 
 CXCL12  ESR1  HSD17B2 STAT5 
 CXCR4 WT1  HSD17B2 PTEN 
 CYP19A1 SF1  HSD3B1 STS 
    
 
TABLE 3.7-A LIST OF GENES/MOLECULES /PROTEINS RELATED TO 
INFLAMMATION IN ENDOMETRIOSIS INPUTTED INTO INGENUITY 
 
 
BRCA1  COL5A2  HLA-G  IL8 
 BRCA2  GRO1  HPGD  PLAT 
 CCL21  GRO2  IL10  PPARG 
 COL4A2  GnRH  IL6  S100A8 
 
 
 
TABLE 3.8- A LIST OF GENES/MOLECULES/PROTEINS RELATED TO 
RETROGRADE MENSTRUATION IN ENDOMETRIOSIS INPUTTED INTO 
INGENUITY 
 
 
ACE  CXCL12  MMP1 MMP9 
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 BSG  CXCR4  MMP2  PRDX2 
 c17orf63  GALT  mmp24  PAI1 
 CFL1  GAPDH  MMP3  TIMP2 
 CHRNB1  HSPB1  MMP7 Twsg1 
XRCC1      
     
 
 
TABLE 3.9- A LIST OF GENES/MOLECULES RELATED TO METASTASIS 
IN ENDOMETRIOSIS INPUTTED INTO INGENUITY 
 
 NOD2 bcl2  GREM1 
 PAX8  COL6A1  GREM1 
 SDC2  COL6A2  IL1 
 THBS1  Erg  IL6 
 VEGFA  ETS1  IL8 
 HOX10  Flt1  LAMA4 
 WNT4  GnRH  MMP1 
 WNT5A MMP2  WNT7A 
 
TABLE 3.10- A LIST OF GENES/MOLECULES ETC RELATED TO 
CALCIUM SIGNALLING IN ENDOMETRIOSIS INPUTTED INTO 
INGENUITY 
 
 AKT1 CYP19A1  HSD17B2  PTEN  spp1 
 Arnt  CYP1B1  KCNK2  PTGS2  SQSTM1 
 ATM  eif3a  Kcnma1  S100A4  StAR 
 ATP2A2  FGF9  mki67  S100P  STAR 
 ATP2C1  H2AX  NANOG  SALL4  TCL1a 
 BMI1  TCL1a  NR2F1  SF1  TERT 
 spp1  TERT  WT1  SOX15  TNFa 
 SQSTM1  TNFa  ZFP42 Q96RL1  UTF1 
 StAR      
     
 
 
 
TABLE 3.11- A LIST OF GENES/MOLECULES RELATED TO 
PROSTAGLANDINS IN ENDOMETRIOSIS INPUTTED INTO INGENUITY 
 
Acta2  DIO2  ERBB4  IGFBP6 IL1R1 
 BMP7  DKK1  VEGFD  IHH ntrk2 
 CCL20  DUSP1  FOXO1A  IL15 SP1 
 CCR6  E2F1  HTRA1  IL17A VEGFC 
 CD55  EGFR  IDO1 PSAP KLF9 
 CXCL14  egfr  IFNAR1 pls3 LAMB1 
 CYP26A1  ERBB2  IGF1 PDCD4 LTF 
 DICER1  ERBB3 PTEN PAPPA SPARC 
VEGFC VCAN MMP2 TXNIP MIR21 
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TABLE 3.12 -A LIST OF GENES/MOLECULES RELATED TO APOPTOSIS 
IN ENDOMETRIOSIS INPUTTED IN ENDOMETRIOSIS 
 
 
 
 AKR1B1  DFFA  Il8 XIAP 
 Bax  DICER1  MIR21  ZEB1 
 Bcl2  EGFR  NCAM1  ZEB2 
 bcl2l13  ERK  NFKB1  
 Dak FCGR3A  PTGES  
SERBP1 Tnfrsf1a  RB1  
 
 
TABLE 3.13- A LIST OF GENES/MOLECULES RELATED TO P450 
ENZYME IN ENDOMETRIOSIS INPUTTED IN ENDOMETRIOSIS 
 
 
 Q6ZQN3  Q6PFW1  Sox2 Q8TCY9 
 Q69YN4  O43314  SPP1  Q8IZJ1 
 Q86TA4  O75695  TERT  O95185 
 A8MTW9  S100A4  Q96RL1  Q9H1C4 
 Nanog  S100P  Q9H3U1  P13051 
 PCNA Q05940  Q6ZN44 Q9BT76 
 
 
TABLE 3.14- A LIST OF GENES/MOLECULES/PROTEINS ETC RELATED 
TO PROGESTERONE RECEPTORS IN ENDOMETRIOSIS INPUTTED INTO 
INGENUITY 
 
 
 
AKR1C1  ERBB 
 AKR1C2  HOXA10 
 AR  PGR 
 CYP17  Pgrmc1 
 CYP19  PTGES3 
SRD5A1 SSH1 
 
 
 
 
 
 
 
 
 
 
 
STEP 2- Ingenuity IPA networks and interfaces showing genes 
differentially expressed in endometriosis in identified pathological 
processes. 
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Below are lists of genes/ proteins etc that were differentially expressed during 
endometriosis under the specific search categories. These were obtained in 
the inter-linking network system from Ingenuity. 
 
All Bioinformatics Images are displayed at the end of Step 2 on a separate 
page. 
 
TABLE 3.15- LIST SHOWING GENES /PROTEINS SHOWN TO BE 
EXPRESSED DURING INFLAMMATION IN PATIENTS  WITH 
ENDOMETRIOSIS ACCORDING TO INGENUITY 
 
BRCA1 SL00A8 GNRH1 
IL10 BRCA2 PPARC 
IL8 IL6 CCL21 
 
 
 
Image 3.16 shows a screenshot of IPA interface of a network composed by a 
gene set listed in the table 3.15. Genes expressed during endometriosis are 
shown by links to ‘endometriosis’ label (red circle). Genes in the grey boxes 
are those from our inputted list, whilst those in the white boxes have been 
formulated by the Ingenuity interface to be involved in the interlinking network. 
 
TABLE 3.17-  LIST SHOWING GENES/PROTEINS RELATED TO 
RETROGRADE MENSTRUATION EXPRESSED IN ENDOMETRIOSIS 
ACCORDING TO INGENUITY 
 
BCL2 TP53 IL8 GSTT1 ICAM1 
IL6 GALT VEGFA RA5GRF1 TNF 
 
Image 3.18 shows a screenshot of the IPA interface demonstrating a network 
composed by a gene set listed in the table 3.17. Genes from this table 
expressed during endometriosis are shown by links to ‘endometriosis’ label 
(red circle). Genes in the grey boxes are those from our inputted list, whilst 
those in the white boxes have been formulated by the Ingenuity interface to 
be involved in the interlinking network. 
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TABLE 3.19- A LIST OF GENES/ PROTEINS ETC RELATED TO ALTERED 
IMMUNE RESPONSES EXPRESSED IN ENDOMETRIOSIS ACCORDING 
TO INGENUITY 
 
ACE INSRR GALT HSPB1 MMP3 
MMP2 MMP24 TIMP2 MMP9 TGFB1 
CXCR4 XRCC6 BSG MMP1 TP53 
 
 
 
Image 3.20 shows a screenshot of the IPA interface demonstrating a network 
composed by a gene set listed in the table 3.19. Genes from this table 
expressed during endometriosis are shown by links to ‘endometriosis’ label 
(red circle). Genes in the grey boxes are those from our inputted list, whilst 
those in the white boxes have been formulated by the Ingenuity interface to 
be involved in the interlinking network. 
 
TABLE 3.21 
LIST OF GENES/ PROTEINS RELATED TO SENESCENCE EXPRESSED 
IN ENDOMETRIOSIS ACCORDING TO INGENUITY 
 
AHR AHRR CYP19A1 GA56 
KDR NFKB1 TNF PTEN 
VIM CCL21 GALT CYR61 
KRAS PPARG TNFRSF1B AR 
EMX2 GSTT1 MMP1 HSD17B1 
MMP3 STS   
 
 
 
Image 3.22 shows a screenshot of the IPA interface demonstrating a network 
composed by a gene set listed in the table 3.21. Genes from this table 
expressed during endometriosis are shown by links to ‘endometriosis’ label 
(red circle). Genes in the grey boxes are those from our inputted list, whilst 
those in the white boxes have been formulated by the Ingenuity interface to 
be involved in the interlinking network. 
 
 
 
 
 
 
TABLE 3.23 
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LIST OF GENES/ PROTEINS RELATED TO ESTROGEN 
RESPONSIVENESS EXPRESSED IN ENDOMETRIOSIS ACCORDING TO 
INGENUITY 
 
CDK1 DKK1 HSD17B2 MMP3 PTEN CXCR4 ESR1 
HSD17B4 MUC1 STS MARCK5 OVGP1 CYP19A1 ESR2 
IL1R2 NFKB1 WT1 CYR61 HSD17B1   
 
 
 
Image 3.24 shows a screenshot of the IPA interface demonstrating a network 
composed by a gene set listed in the table 3.23. Genes from this table 
expressed during endometriosis are shown by links to ‘endometriosis’ label 
(red circle). Genes/proteins in the grey boxes are those from our inputted list, 
whilst those in the white boxes have been formulated by the Ingenuity 
interface to be involved in the interlinking network. 
 
TABLE 3.25- 
 LIST OF GENES/ PROTEINS  RELATED TO METASTASIS EXPRESSED 
IN ENDOMETRIOSIS ACCORDING TO INGENUITY 
 
BCL2 FLT1 IL8 
COL6A2 IL6 SDC2 
IL1A MMP2 CDL6A1 
MMP1 XCL1 LAMA4 
VEGFA CCL28 TNF 
CCL23 GNRH1  
 
 
 
Image 3.26 shows screenshot of the IPA interface demonstrating a network 
composed by a gene set listed in the table 3.25. Genes from this table 
expressed during endometriosis are shown by links to ‘endometriosis’ label 
(red circle). Genes in the grey boxes are those from our inputted list, whilst 
those in the white boxes have been formulated by the Ingenuity interface to 
be involved in the interlinking network. 
 
 
 
 
 
 
 
TABLE 3.27 
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LIST OF GENES/ PROTEINS RELATED TO CALCIUM SIGNALLING 
EXPRESSED IN ENDOMETRIOSIS ACCORDING TO INGENUITY 
 
AHR CDK1 HSD17B2 PTGS2 
SPP1 TNF ATP2B2 CYP19A1 
PTEN RBP4 STAR WT1 
 
 
 
Image 3.28 shows a screenshot of the IPA interface demonstrating a network 
composed by a gene set listed in the table 3.27. Genes from this table 
expressed during endometriosis are shown by links to ‘endometriosis’ label 
(red circle). Genes in the grey boxes are those from our inputted list, whilst 
those in the white boxes have been formulated by the Ingenuity interface to 
be involved in the interlinking network. 
 
TABLE 3.29 
A LIST OF GENES/ PROTEINS RELATED TO PROSTAGLANDINS 
EXPRESSED IN ENDOMETRIOSIS ACCORDING TO INGENUITY 
 
ACTA2 TP53 LIF EGFR IL1R1 
DKK1 NFRK2 PGR IGFB1 DARC 
FOXO1 CYP26A1 CXCR6 MMP2 EFBB2 
MAOA PTEN DUSP1 IHH VEGFC 
 
 
 
Image 3.30 shows a screenshot of the IPA interface demonstrating a network 
composed by a gene set listed in the table 3.29. Genes from this table 
expressed during endometriosis are shown by links to ‘endometriosis’ label 
(yellow circle). Genes in the grey boxes are those from our inputted list, whilst 
those in the white boxes have been formulated by the Ingenuity interface to 
be involved in the interlinking network. 
 
TABLE 3.31 
A LIST OF GENES/PROTEINS RELATED TO PROLIFERATION IN THE 
ENDOMETRIUM EXPRESSED IN THE ENDOMETRIOSIS ACCORDING TO 
INGENUITY 
 
BCL2 CYP191A IL8 ROCK2 BRCA1 CDK1 DYNLL1 
SMAD6 CCR1 FPR2 NRSA1 GREM1 PIK3R1 NFKB1 
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Image 3.32 shows a screenshot of the IPA interface demonstrating a network 
composed by a gene set listed in the table 3.31. Genes from this table 
expressed during endometriosis are shown by links to ‘endometriosis’ label 
(red circle). Genes/ in the grey boxes are those from our inputted list, whilst 
those in the white boxes have been formulated by the Ingenuity interface to 
be involved in the interlinking network. 
 
TABLE 3.33 
A LIST OF GENES/PROTEINS EXPRESSED IN PATIENTS WITH 
ENDOMETRIOSIS BASED ON DATA MINING USING KEYWORDS 
‘ENDOMETRIOSIS MICROARRAY STUDIES’. 
 
ACTA2 IL8 CD163 CCR1 MMP3 MMP9 CXCR
4 
NFKB
1 
CCL2 MMP2 CYR61 CYP26
A1 
NTRK
2 
PBR DKK1 PGR 
CYP19
A1 
NOS3 DNMTI
38 
DNMT3
A 
PTGE
R 
PTGS2 DUSP
1 
PTPN
22 
DNMT1 PTEN FOXO1 ERBB2 S100A
8 
SLC18
A2 
GOS2 SPP1 
EGFR S100A1 HSPA1
A 
HSD17
B2 
TGFB
1 
TGFB1 IHH TNF 
GRAF STAR IL1R1 IL1A VEGF
A 
VEGFC IL6 WT1 
IL18 TNFRSF
1A 
AHR JUN AR BCL2 MAO
A 
 
  
Due to their being almost 16+ interlinked networks of groups of 
genes/molecules/proteins related to endometriosis overall, a screenshot is not 
possible for thesis purposes. Instead the table shows all the genes/proteins 
differentially expressed in endometriosis.  
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BIOINFORMATICS FIGURES FROM STEP 2 
 
IMAGE 3.16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image 3.18 
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IMAGE 3.20 
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IMAGE 3.22 
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Image 3.24 
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Image 3.26 
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Image 3.28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image 3.30 
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Image 3.32 
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STEP 3-Discovery of genes up regulated during endometriosis through 
the use of Genevestigator 
 
Our next target was to define potential regulators of differential gene 
expression associated with endometriosis. For this purpose we needed to 
know vectors of gene expression changes that were not clearly established 
for the majority of endometriosis associated genes.  Therefore we used 
existing published expression data stored and validated by Genevestigator 
software. 
 
 
 
The key above was used to identify which of the coded genes listed were up 
or down regulated. Those genes indicated in bright red were noted as being 
strongly up regulated whilst a majority as can be seen below, was moderately 
up regulated.  
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FIGURE 3.34 
IMAGE TO SHOW A META-ANALYSIS OF THE PROLIFERATIVE GENES 
UP-REGULATED IN ENDOMETRIOSIS 
 
 
 
 
 
 
 
 
 
 
 
 
Those up regulated were BCL2, IL8 (strongly upregulated) and SMAD6. 
Listed on the left in the image showing the Meta-analysis is experimental 
These codes 
indicate the 
genes 
inputted and 
were decoded 
from the 
program. This 
is applicable 
for all the 
images of 
meta-analysis 
images in this 
chapter. 
The genes coded 202859 and 211506, as well as the gene coded 205098, which are all colored deep red, are 
shown to be up regulated in proliferative activity during endometriosis according to meta-analysis studies. All 
the images (figures 3.34-3.44) below showing meta-analysis studies are arranged with the codes of genes 
corresponding to their level of up or down regulation listed below (either colored dark red or green).  
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samples from endometriosis samples compared to control samples from 
normal endometrial tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.35 
AN IMAGE TO SHOW THE META-ANALSIS OF GENES RELATED TO 
INFLAMMATION UP-REGULATED IN ENDOMETRIOSIS 
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Those up regulated were BRCA2, IL6, IL8 (strongly up-regulated), CCL21 and 
S100A8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.36 
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AN IMAGE TO SHOW THE META-ANALYSIS OF GENES RELATED TO 
RETROGADE MENSTRUATION UP-REGULATED IN ENDOMETRIOSIS 
 
 
 
 
  
 
 
 
Those genes up regulated were ICAM1, GSTT, IL8 (strongly up-regulated) 
and IL6. Data obtained for this program was obtained in experiments using 
endometriosis tissues compared to normal ovary tissue as controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.37 
AN IMAGE TO SHOW THE META ANALYSIS OF GENES RELATED TO 
ALTERED IMMUNE RESPONSE UP-REGULATED IN ENDOMETRIOSIS 
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Those genes up regulated were MMP9, MMP1, CXCR4 (strongly up-
regulated), INSRR and TGFB1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.38 
AN IMAGE TO SHOW THE META ANALYSIS OF GENES RELATED TO 
SENESCENCE UP-REGULATED IN ENDOMETRIOSIS 
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Those genes up regulated were AR, NFKB1, AHR, CCL21, MMP3, MMP1 
and GST11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.39 
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AN IMAGE TO SHOW THE META ANALYSIS OF GENES RELATED TO 
OESTROGEN RESPONSIVENESS UP-REGULATED IN ENDOMETRIOSIS 
 
 
 
 
                         
 
 
Those genes up-regulated were CXCR4 (strongly up regulated) CYR61, 
ESR1, IL1R2, MMP3, NFKB1 and OVP1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.40 
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AN IMAGE TO SHOW THE META ANALYSIS OF GENES RELATED TO 
METASTASIS UP-REGULATED IN ENDOMETRIOSIS 
 
 
               
 
Those up regulated were LAMA4, XCL1 (very strongly up regulated), FLT1, 
COL6A2 and MMP1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 95 
FIGURE 3.41 
AN IMAGE TO SHOW THE META ANALYSIS OF GENES RELATED TO 
CALCIUM SIGNALLING UP-REGULATED IN ENDOMETRIOSIS 
 
 
        
 
The following were up regulated AHR, SPP1 (Strongly up regulated), RBP4 
and PTGS2 (Strongly up regulated).  
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FIGURE 3.42 
AN IMAGE TO SHOW THE META ANALYSIS OF GENES RELATED TO 
PROSTAGLANDINS UP-REGULATED IN ENDOMETRIOSIS 
 
 
 
 
                                                                             
 
 
Those up regulated were DKK1, IL1R2 and LTF (strongly up regulated) 
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FIGURE 3.43 
AN IMAGE TO SHOW THE META ANALYSIS OF GENES UP-REGULATED 
IN PATIENTS WITH ENDOMETRIOSIS (BASED ON FULL 
COMPREHENSIVE SEARCH) 
 
 
         
 
 
 
The following were up regulated: 
SPP1 (Strongly up regulated) 
PTGS2 (Strongly up regulated) 
IL8 (Strongly up regulated) 
AR 
CCL2 
IL6 
CXCR4 
SPP1 
MMP9 
NFKB1 
PTPN22 
IL1A 
MMP3 
STAR 
 
 
 
 
 
 
 
FIGURE 3.44 
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AN IMAGE TO SHOW THE COMPARISON OF META ANALYSIS OF 
GENES UP REGULATED IN ENDOMETRIOSIS AND THOSE REGULATED 
IN GASTRIC CANCER. 
 
 
 
 
 
 
 
 
 
Above is a comparison of the Meta analysis studies of genes up regulated 
(colored in red) in both endometriosis and gastric cancer.  We found the 
pattern of gene expression in gastric cancer from Genevistagator to be a 
condition that most closely resembled the expressional pattern of genes in 
endometriosis endometriosis.  Both analysis studies showed that IL8 is 
strongly up regulated in both endometriosis and gastric cancer. SPP1 is up 
regulated strongly in both conditions, and STAR, which is strongly up 
regulated in gastric cancer, is also up regulated in endometriosis. CCL2 and 
IL6 are both moderately up regulated in both conditions. 
 
Gastric 
cancer 
endometriosis 
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Chapter 4: Discussion explained why some of genes/ proteins were up 
regulated and what their significance in the pathology of endometriosis as well 
as gastric cancer may be. 
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STEP 4- Data showing the common regulatory transcription factor for up 
regulated genes during endometriosis. 
 
The next step was inputting the group of up regulated genes provided by 
Genevestigator into Opossum to find out which transcription factor binding 
sites are the most enriched in their promoter regions  
 
TABLE 3.45 
A LIST OF GENES/PROTEINS UP REGULATED IN ENDOMETRIOSIS 
FROM ALL SEARCH CATEGORIES 
 
BCL2 IL8 SMAD6 SPP1 PTGS2 
AR CCL2 IL6 CXCR4 MMP9 
NFKB1 PTPN22 IL1A MMP3 STAR 
CXCR4 CYR61 ESR1 IL1R2 OVP1 
AHR RBP4 DKK1 LTF MMP1 
GST11 LAMA4 XCL1 FLT1 COL6A2 
CCL21 
TGFB1 
GST11 
NFKB1 
BRCA2 
ICAM1 
S100A8 INSRR 
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TABLE 3.46 
A RANKING OF TRANSCRIPTION FACTORS SHOWN TO BE 
CONTROLLING THE GENES UP REGULATED IN ENDOMETRIOSIS 
LISTED ABOVE 
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As can be seen, FOXD3, ranked third highest according the Z-Scoring (higher 
score, less of possibility scoring due to chance), was seen to be the most 
commonly identified transcription factor controlling some of the up regulated 
genes we obtained from our earlier Bio-Informatics work. It targeted 6115 out 
of 38 of the up-regulated genes expressed in endometriosis. It also had 43 
different transcription factor binding sites.  
 
As well as being a readily available transcription (as explained in Chapter 
3:Immunohistochemistry Methodology), no work had been previously 
undertaken in human or animal studies investigating FOXD3 in endometriosis. 
 
 
STEP 5- Data of up regulated genes with FOXD3 and its other 
accessions 
  
The next stage involved using the program UniProt to find any other 
identifiable names for the transcription factor FOXD3 to ensure reliability when 
we later tried to confirm the link between FOXD3 and the group of up-
regulated genes in the networking system of Ingenuity. Species were selected 
only from Human organisms (Homo Sapien) to provide consistency, as all of 
the previous bioinformatics work had been conducted using human (Homo 
Sapien) computational studies in all the software so far.  
 
TABLE 3.47 
A LIST OF THE GENES PROTEINS UP REGULATED IN ENDOMETRIOSIS 
THAT FOXD3 POTENTIALLY CONTROLS 
 
FOXD3 INSRR DKK1 BCL2 
Q9UJU5 ESR1 SPP1 RBP4 
QO1860 NFKB1 IL6 CYR61 
PTGS2 LAMA4 PTPN22 AR 
STAR IL1A SMAD1  
 
FOXD3 and its two other accessions are in bold 
This list was inputted into Ingenuity to confirm the link between FOXD3 and 
the above key up regulated players. 
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STEP 6- Ingenuity IPA interface network confirming a link between 
FOXD3 and set of up regulated genes in endometriosis 
 
We used Ingenuity to input the contents of Table 3.47 to confirm a link 
between FOXD3 and endometriosis. 
 
IMAGE 3.48 
IMAGE SHOWING THE RELATIONSHIP BETWEEN FOXD3 AND THE 
GENES UP REGULATED IN ENDOMETRIOSIS IN THE IPA INTERFACE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 104 
IMAGE 3.48 shows FOXD3 (red circle) involved in the interlinked mapping 
system in Ingenuity. The inserted figures from our list in the mapping system 
are colored in grey.  
 
Even though it is not placed centrally, the map shows how E2F4 (another 
transcription factor) binds to FOXD3. The transcription E2F4 linked to FOXD3, 
increases the activation of BCL2 and has it’s binding increased by IL-6. As 
well, FOXD3 binds to another transcription factor FOXA1, which is part of the 
same family of Fork-head factors. Ingenuity displays how FOXA1 binds to 
Androgen Receptor, as well as increasing the expression of ESR1. Therefore 
it is clear, from the above image and our Ingenuity network, FOXD3 is a key 
major transcription factor in regards to groups of up regulated players in 
endometriosis. 
 
A more detailed explanation will be provided in Chapter 5:Discussion into how 
FOXD3 and some of the key players are related to endometriosis.  We 
conducted immunohistochemistry lab-work validate our findings and observe 
any involvement of FOXD3 in the endometrium of patients with and without 
endometriosis (please refer to Chapter 2: Immunohistochemistry 
Methodology).  
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IMAGE 3.49 
IMAGE SHOWING THE RELATIONSHIP OF ANDROGEN RECEPTOR AND 
OTHER UP REGULATED GENES/MOLECULES/PROTEINS ETC IN 
ENDOMETRIOSIS 
 
 
Androgen receptor (AR) is up regulated in endometriosis (Fig 3.47). Our 
network (Image 3.49) showed that it is also a central figure in relation to other 
up regulated functions. Danazol, which is an agonist of Androgen Receptor, is 
an approved treatment in patients with endometriosis (explained in Chapter 1: 
Introduction). Also, the IPA mapping system shows that other functions that 
are controlled by FOXD3, such as NFKB1, are also seen to bind to AR 
(Androgen Receptor) in a cell-free system. Also as outlined in figure 3.50, 
there is an involvement of Progesterone Receptor (PR) within the network of 
genes up regulated in endometriosis.  
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Therefore based on these findings, we also conducted immunohistochemistry 
labwork to confirm the activity of AR and PR in endometriosis, of which the 
involvement previous authors have already studied. (See Chapter 5: 
Discussion) 
 
 
IMAGE 3.50 
IMAGE SHOWING RELATIONSHIP OF PROGESTERONE RECEPTOR 
WITHIN THE IPA INTERFACE NETWORK INVOLVING UPREGULATED 
GENES IN ENDOMETRIOSIS 
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IMMUNOHISTOCHEMISTRY DATA 
 
 
FOXD3 Immunohistochemistry data. 
 
The slides were blinded prior to intensity scoring of the basal layer glands, 
functional layer glands, in the endometrial stroma and luminal epithelium. 
Scoring was assessed as absent (0), weak (1), moderate (2), strong (3) or 
very strong (4). The slides that had basal layer glands were full thickness 
samples (explained in Chapter 3- Immunohistochemistry Methodology). After 
independently scoring the slides, the scores and slides were double checked 
by my experimental supervisors.  
 
FIGURE 3.51- Micrograph to show an example of the intensity staining  
of fertile control (Rabbit IgG) weak staining in the basal layer gland of 
endometrium during the window of implantation 
 
 
 
 
 
Figure 3.52- Micrograph to show an example of FOXD3 weak staining in 
the basal layer gland of endometrium. 
 
 
 
 
 
 
 
 
 
 
Basal glands in the 
endometrium 
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Figure 3.53- Micrograph to show an example of FOXD3 strong staining 
in the functional layer gland of endometrium 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.54- Micrograph to show an example of FOXD3 very strong 
staining in the functional layer gland and luminal epithelium of the 
endometrium 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Endometrial 
Stromal cells 
Luminal 
epithelium 
Gland in functional layer of 
endometrium 
 
 109 
 
 
 
 
 
 
Reference images were captured after reviewing all of the slides and each 
slide was compared to the representative photos for each score. These 
scores were entered into GraphPad Prism version 5 in order to create Scatter-
graphs and SPSS Statistical Software to discover whether there was any 
statistical significance in our findings.  
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FIGURE 3.55 
A scatter graph showing the comparison of the intensity staining of 
FOXD3 in the glands of the functional layer in the endometrium of 
women with endometriosis to normal fertile patients, at two different 
stages of the menstrual cycle. 
 
 
 
 
  
 
 
Figure legend for all scatter graphs below. 
STAGE 
WOI- Window of Implantation of menstrual cycle 
P- Proliferative phase  
 
SLIDE 
ENDO- Endometriosis sample 
FC- Fertile Control sample 
 
The two graphs show increased staining intensity of FOXD3  
in the functional glands of fertile control patients compared to the functional  
glands of the endometriosis patients. However, in the window of implantation, 
there is a higher staining of FOXD3 in the functional glands of endometriosis 
patients compared to that of the fertile control patients.  
Intensity 
Staining 
Score (0-4) 
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FIGURE 3.56 
A scatter graph showing the comparison of the intensity staining of 
FOXD3 in the endometrial stroma of women with endometriosis to 
normal fertile patients, at two different stages of the menstrual cycle. 
 
 
 
 
The above graphs show increased staining of FOXD3 in the endometrial 
stroma in the proliferative phase in fertile patients compared to patients with 
endometriosis. However in the window of implantation, the staining of FOXD3 
is increased in the endometrial stroma in patients with endometriosis 
compared to fertile control patients. As can be seen, the staining in the stroma 
of FOXD3 was not as strong as that in the glands. This told us that FOXD3 
did not occupy the stromal area as strongly as it did in the epithelium and 
glandular area, so interaction with antigenic sites in the sample was weaker, 
especially in patients with endometriosis.  
 
 
 
 
 
 
 
Intensity Staining 
Scores (0-4) 
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FIGURE 3.57 
A scatter graph showing the comparison of the intensity staining of 
FOXD3 in the luminal epithelium of the endometrium of women with 
endometriosis to normal fertile patients, at two different stages of the 
menstrual cycle. 
  
The above graphs show increased staining of FOXD3 in the luminal 
epithelium of the endometrium in the proliferative phase in fertile patients 
compared to patients with endometriosis. However in the window of 
implantation phase, the staining of FOXD3 is higher in the luminal epithelium 
of the endometrium of patients with endometriosis compared to fertile control 
patients. 
 
 
 
FIGURE 3.58 
A scatter graph showing the comparison of the intensity staining of 
FOXD3 in the basal glands of the endometrium of women with 
endometriosis to normal fertile patients. 
 
Intensity 
Staining Scores 
(0-4) 
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The above graph shows there is little difference in the staining of FOXD3 in 
the basal glands in the endometrium of patients with endometriosis compared 
to normal fertile control patients. However, it must not be forgotten that there 
was 7 full thickness fertile control patient samples compares to 4 full thickness 
endometriosis samples. 
 
STATISTICAL ANALYSIS OF FOXD3 STAINING FINDINGS 
In using a non-parametric Mann-Whitney U test, it was found there was 
significant statistical difference in the glandular (basal + functional gland) 
FOXD3 staining in endometriosis patients in the proliferative phase compared 
to the window of implantation (p=0.008). It was also found that there was 
significant statistical difference in FOXD3 staining in fertile control patients in 
the endometrial stroma in the proliferative phase compared to the window of 
implantation (p=0.03).  
 
It was also found when comparing fertile control to endometriosis in the 
proliferative phase, FOXD3 staining was statistically significant in the luminal 
epithelium (p=0.03), the endometrial stroma (p=0.008) and glandular areas 
(p=0.008).  
 
However, FOXD3 staining is not significantly significant in the Window of 
Implantation in any of the 4-endometrial compartments when comparing fertile 
patients to endometriosis patients. 
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FIGURE 3.59 
A micrograph to show the staining of FOXD3 in the stromal cells and 
glands in the endometrium of a normal fertile control patient (left) 
compared to a endometriosis patient (right), during the window of 
implantation.  
 
   
 
 
FIGURE 3.60 
A micrograph to show the comparison of FOXD3 staining in the 
glandular area of endometrium in a normal fertile control patient (left) to 
an endometriosis patient (right), in the proliferative phase.  
 
  
 
 As can be seen in Figure 3.58, there is a clearer increased intensity of 
staining in the glandular and stromal area in the endometriosis patient 
compared to the normal fertile control patient. 
The darker intensity of staining indicates that in the endometrial sample, there 
were more specific antigens in the endometrial tissue for the FOXD3 antibody 
to bind to.  
Therefore, as can be seen, there is a significant difference in the presence of 
FOXD3 in patients with endometriosis compared to normal fertile patients.  
The increased expression of FOXD3 is explained in Chapter 4: Discussion.  
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PROGESTERONE RECEPTOR (PR) IMMUNOHISTOCHEMISTRY 
RESULTS 
 
The slides were blinded prior to intensity scoring of the basal layer glands, 
functional layer glands, endometrial stroma and luminal epithelium. Scoring 
was assessed as absent (0), weak (1), moderate (2) or strong (3). The slides 
that had basal layer glands were full thickness samples (explained in Chapter 
3- Immunohistochemistry Methodology).  
 
 
FIGURE 3.61 
A scatter graph showing the comparison of the intensity staining of 
Progesterone receptor in the glands of the functional layer in the 
endometrium of women with endometriosis (ENDO) to normal fertile 
control (FC) patients, at two different stages of the menstrual cycle. 
 
 
  
Figure legend for all scattergraphs below 
STAGE 
WOI- Window of Implantation of menstrual cycle 
P- Proliferative phase  
 
SLIDE 
ENDO- Endometriosis sample 
FC- Fertile Control sample 
 
Intensity 
staining 
scores (0-
3) 
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FIGURE 3.62 
A scatter graph showing the comparison of the intensity staining of 
Progesterone receptor in the endometrial stroma of women with 
endometriosis (ENDO) to normal fertile control (FC) patients, at two 
different stages of the menstrual cycle. 
 
  
 
FIGURE 3.63 
A scatter graph showing the comparison of the intensity staining of 
Progesterone receptor in the luminal epithelium of the endometrium of 
women with endometriosis (ENDO) to normal fertile control (FC) 
patients, at two different stages of the menstrual cycle. 
  
 
 
 
 
Intensity 
staining 
score (0-3) 
Intensity 
Staining 
Scores (0-
3) 
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FIGURE 3.64 
A standard deviation scatter graph showing the comparison of the 
intensity staining of Progesterone receptor in the basal glands of the 
endometrium of women with endometriosis (ENDO) to normal fertile 
control (FC) patients. 
 
 
 
Statistical Significance of Progesterone Receptor staining intensity in 
patients in endometriosis compared to normal fertile control patients 
 
There was no statistical significance according to the SPSS stats in the 
progesterone receptor intensity staining in the endometrium at collectively or 
at any time point (proliferative or window of implantation) of endometriosis 
patients compared to normal fertile control patients. As well, there was no 
statistical significant difference between intensity staining of progesterone 
receptor in any of the 4 compartments within the endometrium in the two 
groups. Therefore, it is clear from the statistical significance data and the 
graphs listed, we could not conclude there to be a difference in the expression 
of Progesterone Receptors in patients with endometriosis compared to normal 
fertile control patients.  
 
 
 
 
 
 
 
Intensity 
Staining 
Scores (0-
3) 
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ANDROGEN RECEPTOR (AR) IMMUNOHISTOCHEMISTRY RESULTS  
 
The slides were blinded prior to intensity scoring of the basal layer glands, 
functional layer glands, and endometrial stroma and luminal epithelium. 
Scoring was assessed as absent (0), weak (1), moderate (2) or strong (3). 
The slides that had basal layer glands were full thickness samples (explained 
in Chapter 2- Immunohistochemistry Methodology).  
 
 
FIGURE 3.65 
A scatter graph showing the comparison of the intensity staining of 
Androgen receptor in the glands of the functional layer in the 
endometrium of women with endometriosis (ENDO) to normal fertile 
control (FC) patients, at two different stages of the menstrual cycle. 
  
Figure legend for all scattergraphs below 
STAGE 
WOI- Window of Implantation of menstrual cycle 
P- Proliferative phase  
 
SLIDE 
ENDO- Endometriosis sample 
FC- Fertile Control sample 
 
 
FIGURE 3.66 
A scatter graph showing the comparison of the intensity staining of 
Androgen receptor in the luminal epithelium of the endometrium of 
Intensity 
staining 
scores (0-
3) 
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women with endometriosis (ENDO) to normal fertile control (FC) 
patients, at two different stages of the menstrual cycle. 
 
  
FIGURE 3.67 
A scatter graph showing the comparison of the intensity staining of 
Androgen receptor in the endometrial stroma of women with 
endometriosis (ENDO) to normal fertile control (FC) patients, at two 
different stages of the menstrual cycle. 
 
  
 
 
 
 
 
Intensity 
Staining 
Scores 
(0-3) 
Intensity 
Staining 
score (0-3) 
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FIGURE 3.68 
A scatter graph showing the comparison of the intensity staining of 
Androgen receptor in the basal glands of the endometrium of women 
with endometriosis (ENDO) to normal fertile control (FC) patients. 
 
 
 
 
 
 
Statistical Difference of Androgen Receptors in the endometrium in 
patients with endometriosis compared to normal fertile control patients 
 
Similarly to the significance of Progesterone Receptor staining, there was no 
statistical significance according to the SPSS stats in the androgen receptor 
intensity staining in the endometrium at collectively or at any time point 
(proliferative or window of implantation) of endometriosis patients compared 
to normal fertile control patients.  
As well, there was no statistical significant difference between intensity 
staining of androgen receptor in any of the 4 compartments within the 
endometrium in the two groups. Therefore, it is clear from the statistical 
significance data and the graphs listed, we could not conclude there to be a 
difference in the staining of androgen Receptors in patients with 
endometriosis compared to normal fertile control patients.  
 
 
 
 
 
 
 
 
Intensity of 
Staining 
Scores (0-
3) 
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TABLE 3.69 
A TABLE OF DEMOGRAPHICS OF PARTICIPANTS (ENDOMETRIOSIS 
AND FERTILE CONTROL PATIENTS) USED IN THE STUDY 
 
Sample Age Parity 
BMI 
(Body 
Mass 
Index) Cycle length 
Endometriosis 
stage 
SPCE29 49 2 32.7 28   
SPCN11       
       
SPCN37 40 1 30.1 28   
SPCN40-
2 37 2 26.5 28   
RM260 36      
SPCE21-
1 33 2 20.3 28 1 2  
SPCE2 45 0 32 28 2  
SPCE17 33 0 22.2 32 3  
SPCE23-
1 41 2 27.8    
SPCN23 42 4 35.8 28   
EN55 36 1 31.4 28 3  
EN39 41 1  28 4  
SPCN27 30 3 28.1 30   
EN56 30      
SPCN17 32 4 22.8 28   
SPCN32-
1 28 1 29.7 28   
EN09 35 0 24 26   
       
SPCN31 40 2 34.3 28   
SPCN20 43 0 26.7 28   
SPCN33 44 2 24.3 28   
SPCE30 38 0 23.3 28 1  
 
 
From our results, we found there was significant difference in the expression 
of FOXD3 in patients with endometriosis compared to those without. We can 
predict genes controlled by this transcription factor up regulated from our 
bioinformatics study, were increased in these patients.  
The immunohistochemistry procedures were able to provide a definitive 
confirmation of FOXD3 being present in patients with endometriosis.   Using 
the table of demographics listed above of patients as well as earlier 
bioinformatic findings, we explained in the next chapter (Chapter 4: 
Discussion) why FOXD3 staining was significantly different in patients with 
endometriosis compared to fertile control patients. With no relevant studies on 
FOXD3 and its involvement in the pathology of endometriosis, we hoped to 
 122 
provide a possible breakthrough in future work for diagnostic and therapeutic 
purposes. 
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CHAPTER 4: DISCUSSION 
 
In Chapter 3, we showed how bioinformatics and computational technology 
were used to discover key genes up regulated in various pathological 
processes during endometriosis. We were able to discover some common up 
regulated genes/proteins in these different cellular aberrations and relate this 
expressional pattern to other conditions. The interlinking of the identified 
genes in the pathological processes related to endometriosis will be explained 
in this chapter.  
 
With the use of bioinformatics, we identified FOXD3 in the pathogenesis of 
endometriosis. It was found that it played a regulatory role in a large number 
of genes that have been already published and known to be associated with 
endometriosis. In validating our bioinformatics findings, we conducted 
immunohistochemistry (IHC) work to discover whether FOXD3 was expressed 
in the human endometrium, and aberrantly expressed in the eutopic 
endometrium of patients with endometriosis. 
 
Our bioinformatics findings also showed Androgen receptors (AR) and 
Progesterone Receptors (PR) to be involved in the interlinking pathways of 
genes during endometriosis. Previous authors had suggested AR and PR to 
be involved in the pathogenesis of endometriosis with the use of IHC 
laboratory work. Therefore we conducted an IHC study of the same 
endometrial samples to investigate if there is a difference in the expression of 
AR and PR between the normal endometrium and the eutopic endometrium of 
patients with endometriosis.  
 
Our extended IHC showed that FOXD3 is expressed in the human 
endometrium for the first time. There was a statistically significant difference 
in the semi-quantitative staining scores between patients with endometriosis 
and normal fertile control patients in the glandular areas, luminal epithelium 
and stromal area in the endometrium during the proliferative phase of the 
menstrual cycle. On the contrary, we could not find a significant difference in 
 124 
the staining of androgen and progesterone receptors in the endometrium of 
patients with endometriosis compared to normal fertile control participants.  
  
4.1 Discussion of the main Bioinformatics findings 
 
 
As seen in Chapter 3: Data and Analysis, the use of bioinformatics made it 
possible to identify that there are certain genes that appear to be commonly 
up regulated in endometriosis and its related pathological processes.  With my 
bioinformatics, we found IL-8, StAR, CXCR4, PTGS2, SPP1 and CXCR4 
were seen be to be very strongly up regulated in the various pathological 
events related to endometriosis. The genes displayed a link between common 
processes. From the meta-analysis provided by Genevestigator, we found 
similar expressional patterns of SPP1, IL-8, StAR and CXCR4 in gastric 
cancer.  I will therefore discuss each of the individual genes/proteins as well 
as the available evidence for their involvement in endometriosis and other 
pathological conditions and how they may be involved in the disease process. 
 
4.1.1-The expression of Secreted Phosphoprotein-1 (SPP1) 
SPP1 was seen to be a gene strongly up regulated in endometriosis and also 
within the related pathological process calcium signalling. SPP1, also known 
as osteopontin (OPN) was regulated by FOXD3 in its transcriptional activities. 
(117)  
SPP1 has been seen to be important in bone remodelling and anchoring 
osteoclasts to the mineral part of the matrix in the bone. (117) It is also 
important in the function of the immune system, inhibiting the production of 
the cytokine IL-10 (Th2 cytokine), therefore promoting the function of the Th1 
cytokine and influencing a cell-mediated immunity.  
There is available evidence that has studied the expression of SPP1 (OPN) 
within endometriosis. Cho et al in 2009 showed how osteopontin (SPP1) 
expression was increased in patients with endometriosis and how plasma 
levels of SPP1 may be used as a non-invasive marker for the diagnosis of 
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endometriosis. (117) Odagiri et al in 2007 also displayed how SPP1 played an 
important role in the pathogenesis of endometriosis. (118) Odagiri found that 
OPN was stained strongly in the glandular areas of the endometrium in both 
human and rat endometriotic tissue samples. (118) However in contrast, Wei 
et al in 2009 showed that there was a decreased expression of SPP1 in the 
late secretory phase in patients with endometriosis, indicating that this may be 
linked to the impaired endometrial receptivity in endometriosis patients. (119) 
 SPP1 is a common protein that regulates macrophages during an 
inflammatory response at sites of chronic inflammation. We suggest that OPN 
is largely up regulated in the endometrium due to the increase in 
concentration of macrophages and other cytokines in the pelvic cavity. (117) 
The increased macrophage concentration is important in processing the 
foreign invading endometrial cells, and producing antigen-presenting cells for 
the antibodies. Therefore OPN may be strongly up regulated in endometriosis 
due to the increased macrophage production in the pelvic peritoneum as well 
as the altered immune response that occurs.  
There is available evidence to suggest a link between OPN and calcium 
signalling. You et al in 2001 investigated the regulation of OPN by oscillatory 
fluid flow via intracellular calcium mobilization and the activation of mitogen-
activated protein kinase in osteoblasts. (120) The study outlined how OPN 
regulation would increase after a 2-hour oscillatory fluid flow involving calcium 
ions. (120) We understand that an increase in intracellular calcium (Ca2+) 
and mitogen activated protein kinase (MAPK) during calcium signalling in the 
endometrium is therefore likely increase the regulation of OPN. Additionally 
Khoshniat et al in 2011 investigated how the Phosphate-dependent 
stimulation of OPN expression in osteoblasts through ERK1/2 pathway is 
modulated by calcium. (121) This study showed how calcium and it’s 
signalling pathway played a role in the functioning of osetoblasts, increasing 
the expression of Phosphate and OPN. (121) 
We can therefore predict in the uterus, the flow of calcium ions and its 
signalling pathway inducting the contraction of myocyte cells in the 
myometrium may up regulate SPP1 during endometriosis. 
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We also found SPP1 (OPN) to be very strongly up regulated in gastric cancer. 
Studies such as that by Junilla et al in 2011 have shown how there has been 
over expression of SPP1 in metastasized tumours. (125) SPP1 is an 
important mediator in stress response, cell adhesion and angiogenesis and 
therefore is seen to play a pivotal role in the metastasis and angiogensis in 
cancer. (122) Chang et al in 2011 studied how an increased gastric 
expression of SPP1 (OPN) by Helicobacter Pylori infection may correlate with 
a more severe gastric inflammation and intestinal metaplasia. (122) In gastric 
cancer, inflammation of the intestinal epithelium progresses to metaplasia 
eventually resulting in adenocarcinoma of the cells.  
 We can predict SPP1 to carry out similar roles in gastric cancer to 
endometriosis through its inflammatory, adhesive and angiogenesis functions.  
4.1.2- The expression of Interleukin-8 (IL-8) 
According to our bioinformatics findings, IL-8 was strongly up regulated in 
proliferation of the endometrium, retrograde menstruation and inflammation in 
with endometriosis.  
IL-8 is a cytokine immune factor that induces neutrophil chemotaxis at site of 
inflammation. Past studies have confirmed our findings of IL-8 playing an 
important role in the proliferation of the endometrium in endometriosis. (123) 
Arici et al in 1998 showed that IL-8 directly stimulates the growth and 
proliferation of endometrial cells. (123) The study showed that there was an 
increase in the proliferative activity of endometrial cells in correspondence to 
the in vivo concentration of IL-8. Therefore the increase in the concentration 
of IL-8 in the peritoneal fluid of endometriosis patients provides a plausible 
explanation of there being an involvement in the growth of menstrual debris 
from retrograde menstruation. Another study from Ulukus et al in 2009 
investigated IL-8 levels to be highest in the eutopic endometrium of patients 
with endometriosis during the proliferative phase. (124) Refluxed endometrial 
cells that attach to the extracellular matrix and outside the pelvic peritoneum 
are likely to secrete higher levels of IL-8. (123) In response, granulocytes are 
recruited and an inflammatory reaction will occur.  
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The bioinformatics data from Genevestigator also showed IL-8 to be up 
strongly up regulated in both gastric cancer and endometriosis. A study by 
Bartchewsky et al in 2009 found that there were higher levels of IL-8 and 
COX-2 detected in the gastric mucosa of patients. (126) Up-regulation of this 
interleukin occurred in correspondence to H-pylori causing cellular 
proliferation and gastric mucosal damage, resulting in the development of 
gastric adenocarcinoma. (126) Ju et al in 2010 showed that IL-8 associated 
with adhesion, migration, and invasion in gastric cancer cells. Similarly to our 
bioinformatics findings, Ju et al found IL-8 to be over expressed in gastric 
tumour cells, and discovered it to promote cell adhesion in endothelial cells as 
well invasion in gastric cancer. (127) 
 
Being an important interleukin during the inflammatory processes, we can 
suggest IL-8’s function of being involved in the proliferative and reflux activity 
of endometrial cells can be compared to the function of the mediator during 
it’s interaction with H-Pylori in the gastric mucosa. Therefore a similarity can 
be predicted in the strong up regulation of IL-8 during the pathogenesis of 
endometriosis and in gastric adenocarcinoma. 
4.1.3- The expression of CXCR4 
CXCR4 was up regulated in the altered immune responses and oestrogen 
responsiveness during endometriosis according to our bioinformatics findings.  
 
The CXCR4 gene encodes a specific CXC chemokine receptor and 
endometriosis is a process in which local inflammatory factors are activated. 
Studies such as that by Ruiz et al in 2010 have reported CXCR4 levels to be 
higher in endometriosis patients and this could be responsible for the survival 
of ectopic endometrial cells implanted. (128)  
Many studies have identified a link between CXCR4 signalling and Oestrogen 
receptor signaling pathways in breast cancer. Furuya et al in 2007 
investigated how CXCR4 signaling contributed to the Oestrogen-receptor 
dependent gene expression and therefore the growth of breast cancer cells. 
Furuya also predicted that oestrogen receptor expression was activated by 
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SDF-1 in the presence of CXCR4. (129) Other studies have also confirmed 
17β-estradiol (E2) to increase the expression of CXCR4 and CXC12 in 
oestrogen receptors. (129) 
   
With endometriosis being an oestrogen dependent disease and requiring the 
hormone for growth of ectopic lesion, we can predict CXCR4 to be up 
regulated in the same way as it is in breast cancer.  
 
Breast cancer, like endometriosis, is an oestrogen dependent disease and the 
growth of cancer cells is dependent on oestrogen receptor levels. However 
Ruiz et al found CXCR4 to be down-regulated by ovarian steroid hormones in 
endometrial epithelial cells. (128) Therefore, from our bioinformatics findings, 
we can predict CXCR4 to be up regulated in patients with endometriosis due 
to an altered immune response (involvement of inflammatory mediators).  
 
4.1.4- The expression of Steroidogenic acute regulatory protein (StAR) 
The StAR protein was observed as being up regulated during endometriosis 
as well being strongly up regulated in gastric cancer. Studies have shown the 
levels to be highest in the ectopic implants of early endometriosis. (130) StAR 
is a transport protein that regulates cholesterol transfer within the 
mitochondria and it is a rate-limiting step in oestrogen production and the 
production of other steroid hormones. (130) Tsai et al in 2001 showed how 
StAR expression in ectopic endometriotic tissue implants leads to increased 
peritoneal progesterone production, which is an important part of the 
pathology of endometriosis. (130) As well, Tian et al in 2009 studied how 
StAR expression is associated with the severity of endometriosis. (131) 
Immunohistochemistry was used in this study to evaluate the levels of StAR in 
the endometrium of women with and without endometriosis. (131) It was 
found the expression of StAR was higher in ectopic endometrial tissue and 
increasing expression correlated with the severity of the disease in the 
patients. (131) Therefore, with endometrial cells requiring oestrogen and 
progesterone in their growth and development, StAR is strongly up regulated, 
as it is a rate-limiting step in the production of these steroid hormones.  
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Akiyama et al in 1997 showed how CAB1, a gene expressed in gastric cancer 
cells, was seen to be homologous to StAR, therefore indicating its possible 
role in gastric cancer. (132) StAR is primarily present in steroid-producing 
cells such as the theca and luteal cells in the ovary. (132) Some metastatic 
carcinomas in the ovary such as the Krukenbergs tumor are derived from a 
primary malignancy in the gastrointestinal tract. (132)  
With StAR playing an important role in cholesterol transport to the 
mitochondria, it could seen to be involved in the cellular survival and growth in 
both endometriosis implants and gastric cancer cells.  
 
4.1.4- The expression of Prostaglandin-endoperoxide synthase 2 (PTGS2) 
Our bioinformatics findings showed PTGS2 to be strongly up regulated within 
endometriosis, as well as during calcium signalling.  PTGS2 which is also 
known as COX-2, is an enzyme encoded by the PTGS2 gene. 
There is available evidence showing a link between the expression of PTGS2 
and endometriosis. Liu et al in 2011 found PTGS2 promoter transcription 
activity to be increased in endometrial cells in endometriosis. (77) Cho et al in 
2009 found that PTGS2 to be over expressed in the eutopic endometrium and 
ovarian endometriotic tissue in patients with endometriosis. (133) As 
explained in Chapter 1, PTGS2 (COX-2) is an important enzyme involved in 
the production of prostaglandin, one which contributes to pain and 
inflammation within endometriosis patients.  
Our bioinformatics finding also showed that PTGS2 is up regulated during 
calcium signaling, a pathological process related to endometriosis. We 
propose that PTGS2 is up regulated in patients as prostaglandin production is 
increased during endometriosis. During endometriosis, pelvic pain and other 
related symptoms are likely to be a resultant of the increased contractions of 
the uterus. (76) Therefore, with a rise in prostaglandins in patients, this will 
bind to a G-Coupled receptor activating adenylyl cyclase and the protein 
kinase A (PKA). As a result, Ca 2+ ions influx and myometrial contractility 
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may occur. (76) Therefore up regulation of the enzyme PTGS2 may be 
related to calcium signaling in endometriosis.  
 
 
4.2- Discussion of IHC findings 
 
4.2- IHC OF FOXD3 
 
Many studies have provided information on up or down regulated genes in 
endometriosis. It is difficult to understand the pathogenesis of endometriosis 
clearly due to the fragmented nature of the available evidence on the 
involvement of these genes in the disease. With plausible explanation being 
put forward in previous studies for the involvement of proteins such as IL-8, 
PTGS2, StAR, CXCR4 and SPP1 in endometriosis, breakthrough information 
into further possible theories of pathogenesis has failed to emerge.  
Bioinformatics provided a useful tool to identify key transcription factors such 
as FOXD3 and FOXI1 that may regulate many of these separate pathological 
processes and genes. 
 
From this data and the hypothesis generated from our bioinformatics study, 
we then progressed to test the involvement of one of the identified 
transcription factors in the human endometrium by carrying out a laboratory 
study. We focused on one of the common transcription factors, FOXD3 that 
seemed to regulate a large number of those genes that have already been 
reported to be involved in the pathogenesis of endometriosis and found a 
greater intensity of staining in the endometrium of patients with endometriosis 
compared to normal fertile control patients. The following is a list of 
genes/proteins up regulated in endometriosis that are controlled by FOXD3. 
 
PTGS2 INSRR DKK1 BCL2 
STAR ESR1 SPP1 RBP4 
IL1A NFKB1 IL6 CYR61 
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SMAD1 LAMA4 PTPN22 AR 
    
 
 
 
4.2.1 FOXD3 expression within the normal endometrium  
 
From our IHC findings, we found FOXD3 to be expressed in all areas of the 
normal endometrial during the proliferative phase. According to our work, 
there was a strong expression of FOXD3 in the luminal epithelium and 
glandular areas in the normal endometrium. The expression in endometrial 
stroma was not as strong as it was in the luminal epithelium and glandular 
locations, however there was moderate expression seen similarly in the basal 
layer glands.   
 
We found there to be a decreased expression of FOXD3 from the proliferative 
to the secretory phase. There was seen to be a poor expression of FOXD3 in 
the endometrial stroma during the secretory phase, whilst the expression of 
FOXD3 in the luminal epithelium and glandular areas of the normal 
endometrium was much lower than it was in the secretory phase.  
 
Expression of FOXD3 has been shown to promote neural crest induction and 
the transcription factor will be activated upon the emergence of neural crest 
cells, providing importance for the maintenance of stem cells. (134) Neural 
crest (NC) cells are progenitor multipotent cells that contribute to a number of 
derivatives. (135) Studies have shown FOXD3 to be detected in early 
embryogenesis within mice, playing an important role in maintaining the small 
population of cells in the epiblast (inner cell mass in mammals). (134)  
FOXD3, a transcriptional regulator that is expressed in embryonic stem cells, 
is seen to play an important role in the maintenance of proliferative and 
renewing progenitor stem cells. Embryonic stem cells, derived from 
blastocysts, can differentiate into cells of different lineage. (135) The stem 
cells can divide to produce daughter (progenitor) cells. (135) 
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On a cellular level, FOXD3 was shown to stain within the nucleus of luminal 
epithelial cells and the cytoplasm of stromal cells.  
Figure 4.2.2 
An immuno-fluorescence image to show the presence of FOXD3 within the 
stromal and luminal epithelial cells in a cultured normal human endometrium 
sample 
 
 
The immuno-fluorescence image above shows the luminal epithelial cells, 
which is stained by the expressed cytokeratin. Surrounding this are the 
endometrial stromal cells. FOXD3 is shown to stain centrally (purple) in the 
nucleus of the luminal epithelial cell.  
 
4.2.3- FOXD3 Expression in the eutopic endometrium of women with 
endometriosis 
 
We found the expression of FOXD3 to be proportionately higher in the glands 
and luminal epithelium of endometrium in women with endometriosis 
compared to normal fertile control patients. In contrast to the change seen of 
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FOXD3 in the normal endometrium, we found there to be an increase in the 
expression of FOXD3 from the proliferative phase to the secretory phase 
within endometriosis.  
 
The expression of FOXD3 in the endometrial stroma in endometriosis patients 
in the proliferative phase was weak, however increasing Slightly in the 
secretory phase.  
 
There is a very strong expression of FOXD3 in the luminal epithelium and 
glands in the endometrium of endometriosis patients in the secretory phase. 
The expression of FOXD3 in these compartments during the secretory phase 
is higher than the FOXD3 expression in the normal endometrium during the 
proliferative phase. Thus, these findings indicate that there is a greater 
expression of FOXD3 in the glandular areas and luminal epithelium in the 
endometrium of women with endometriosis compared to normal control 
patients.  
 
We can suggest some possibilities into why there is a higher expression of 
FOXD3 in patients with endometriosis. FOXD3 has a greater role in patients 
with endometriosis due to the increased development of stem/progenitor cells.  
 
The endometrial lining of the uterus displays functions of stem cell 
regeneration. 
A study by Leyendecker et al in 2009 compared the expression pattern of 
progesterone receptors, oestrogen receptors and P450 aromatase in the 
normal endometrium to ectopic endometrial implants. (136) It was found that 
the basalis layer of the endometrium, which possessed endometrial 
stem/progenitor cells, was shed in greater quantities in the menstrual flow in 
endometriosis patients. (136) This showed endometrial implants occur due to 
retrograde menstruation of endometrial stem/progenitor cells. (136) Bone-
marrow derived stem cells targeting the uterus may differentiate into 
functional endometrium. This observation may be responsible for supporting 
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the coelomic metaplasia theory explained in Chapter 1, in which extrauterine 
stem/progenitor cells can travel to ectopic sites through the lymphovascular 
spaces. (136) 
With Leyendecker et al suggesting more basalis layer is shed in the 
endometrium of patients with endometriosis, in response; there will be a 
greater production and regeneration of the lost stem cells. Sampsons theory 
proposes these shed endometrial cells will be implanted ectopically. These 
stem cells continually divide and grow to form progenitor cells. The increased 
activity of these embryonic stem cells consequently increases the expression 
of FOXD3.   
 
4.2.4- The Functions of FOXD3 
We can predict FOXD3 works with other expressed genes/proteins, binding to 
specific DNA sequences to act as a transcription factor.   OCT-4 (also known 
as POU5F1) is also highly expressed in the embryonic stem cells. (137) Oct-4 
maintains the undifferentiated state of embryonic stem cells. (137)  
POU5F1 (Oct-4) decreases the activation of transcription factor FOXA1 and 
FOXA2, whilst FOXD3 increases the activation of them when it is expressed. 
The negative feedback involving these transcription factors contributes to the 
functioning of FOXD3 in its regulation of genes/proteins.  We can suggest the 
repression of the transcriptional activation of FOXA1 and FOXA2 by Oct-4, is 
benefitting to FOXD3 functioning as a transcription factor. (137)  
FOXA1 and FOXA2 bind to the DNA with the sequence 5'-
[AC]A[AT]T[AG]TT[GT][AG][CT]T[CT]-3' and are involved in the regulation of 
apoptosis through inhibiting the expression of BCL2. (137) In referring back to 
Table 4.44, we discovered FOXD3 to activate regulation of BCL-2, which was 
seen in figure 3.32, to be up regulated during proliferative activity during 
endometriosis.  
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We suggest through the shedding of endometrial cells, as well as the 
migration, implantation and adhesion of ectopic endometrial cells, embryonic 
stems cells in these ectopic implants will produce FOXD3 and Oct-4.  
This process of repair and regeneration of tissue promotes the recruitment of 
immune-related factors such as SPP1, CXCR4 and those mentioned earlier. 
We propose that the expression of the listed genes/proteins in table 3.44 
during the various pathological processes (in endometriosis) may be 
dependent on the production of FOXD3 by embryonic stem cells.  
 
4.3- IHC of AR/PR 
 
To further validate our bioinformatics findings we also conducted an IHC 
examination of the same endometrial samples for the expression of androgen 
and progesterone receptors. Both receptors have already been implicated by 
other authors to be involved in the pathology of endometriosis as well as 
being highlighted in playing a role in the pathogenesis from our bioinformatics 
investigations.  
 
However, our IHC study did not show a statistically significant difference in the 
staining of progesterone and androgen receptors in the endometrial samples 
from women with endometriosis.  
 
4.3- Discussion of Androgen Receptor (AR) expression  
There is available evidence to show the change in expression of AR in the 
normal endometrium across the menstrual cycle. Horie et al in 1992 examined 
14 women with normal menstrual cycle for the expression of AR in the 
endometrium. There was seen to be a high expression of AR in the 
endometrium in both the proliferative and secretory phase in the normal 
endometrium. (33) There was a higher expression of AR in the stromal cells 
and glands of the functional layer compared to those in the basal layer. (138) 
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Mertens et al in 1996 however showed a greater contrast in the expression of 
AR in the endometrium over the two cycles. (139) It was found that AR 
expression was higher in the proliferative phase than in the secretory phase. 
(139) Mertens et al also discovered the expression of AR was higher in the 
stromal cells of the endometrium in proliferative phase. (139) The expression 
of AR in the epithelial cells was seen to be highest in the secretory phase. 
(139)  
There is also evidence suggesting varied expression of AR in the 
endometrium of endometriosis patients. Carneiro et al in 2008 found an 
increase in the expression of AR in glandular and endometrial stromal cells in 
the eutopic and ectopic endometrium. (140) This increased expression of AR 
in the endometrium suggests a role in the pathogensis of AR in 
endometriosis. The study indicates androgens may be formed within 
endometriotic tissue and that local and systemic androgens can act on 
endometriotic cells. This gives a plausible explanation into why danazol (as 
explained in Chapter 1: Introduction) may inhibit endometrial cell growth.  
Our findings showed a slight decrease in the expression of AR in the glands 
of the functional layer from the proliferative phase to the secretory phase. The 
expression of AR in the luminal epithelium decreased as well from the 
proliferative phase to the secretory phase in the normal endometrium. This 
finding differs to that found in Mertens et al, which states AR expression in the 
luminal epithelium is highest in the secretory phase. Our study found AR 
expression in the stroma to be very high in the proliferative phase, decreasing 
slightly in the secretory phase. This is similar to that of Mertens et al, which 
stated AR stromal expression is higher in the proliferative phase in the normal 
endometrium. The expression in the basal glands is also low in the normal 
endometrium, which correlates to his findings. 
Our findings displayed that there was no change in expression of AR in the 
endometrial stroma in the endometrium of patients with endometriosis. There 
was no change in the expression of AR between the proliferative and 
secretory phase. There was also no change seen in the expression of AR in 
the basal or functional layer glands between patients with endometriosis and 
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the normal endometrium. Therefore our findings differed greatly to other 
published studies such as those found by Carneiro et al in 2008. 
4.4- Discussion of Progesterone receptor (PR) expression 
 
There is available evidence, which suggests that there is PR expression in the 
normal endometrium.  
Jones et al in 1995 discovered that progesterone receptor expression in the 
luminal epithelial and glandular cells decreased significantly between the 
proliferative and secretory phases in the normal eutopic endometrium. (22) 
PR expression in the eutopic endometrium of endometriosis patients was 
found not to differ from the control endometrium. (141) Also, stromal 
progesterone expression was reduced in the ectopic endometrium of 
endometriosis patients during the cycle. (141) 
 
Nisolle et al in 1994 showed that the highest concentration of PR occurred in 
the epithelial and stromal in the late proliferative phase of the menstrual cycle 
and decreased greatly. (142) Nisolle et al stated that in peritoneal 
endometriotic lesions, the highest concentrations of PR were found during the 
late proliferative phase in the epithelial and stromal cells. (142) 
 
PR is usually expressed as two isoforms, PR-A and PR-B, arising from the 
same gene. (144) The two receptors are identical in the DNA binding domain 
(DBD) and C- terminal ligand binding domain (LBD). (144) There is seen to be 
functional differences in both receptors with PR-A possessing more 
importance in the uterus and ovary. (144) 
 
Fazleabas et al in 2010 developed the baboon model of induced 
endometriosis, explaining the retrograde menstruation hypothesis. The study 
suggested there was a progesterone resistance and decreased 
responsiveness of the progesterone receptor (PR) in patients. (143) The study 
notes progesterone resistance to be a gradual process, which may become 
evident after 6 months of having the disease. (143)  
Attia et al found PR-B to be present in 17 out of 18 eutopic endometrial 
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samples, and found its level to be increased in the pre-ovulatory phase. (144) 
PR-A was detected in all samples but in lower levels than PR-B. (144)  
 
There was no change seen in the expression of PR in the glands of the 
normal endometrium from the proliferative to the secretory phase. Similarly, in 
the stroma of the normal endometrium, there was seen to be no clear cyclic 
change in the expression of PR. These findings differ to those already 
published on the changes of PR expression in the normal endometrium.  
 
The expression of the luminal epithelium slightly decreases from the 
proliferative to secretory phases. Similarly, this finding differs to Nisolle et al’s 
study, which states the change is quite predominant.  
 
Our experimental findings showed that there was no cyclic change (increase 
or decrease) in the expression of PR in the epithelium and the basal layer 
glands in the endometrium between patients with and without endometriosis. 
We also found the change in PR expression in the stromal and functional 
layer glands in the endometrium in endometriosis to be statistically 
insignificant.  
 
There are many conflicting studies that provide differing ideas into how PR 
expression may or may not change during endometriosis. Therefore, our 
findings agree with some ideas suggested by Jones et al in 1995 however 
conflicting the proposals stated by Fazleabas et al in 2010. 
 
The genes/proteins up regulated within the pathological events during 
endometriosis explained in previous chapters were controlled by transcription 
factor FOXD3. We have shown that FOXD3 is expressed in the human 
endometrium and aberrantly expressed in the endometrium of women with 
endometriosis. 
4.5- Deficiencies of the study 
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There were a few deficiencies and flaws within our study. We feel the 
following issues may have contributed to our study obtaining insignificant data 
when investigating the AR and PR staining in endometriosis, possibly 
hindering us from obtaining a true result. 
The first deficiency was the small sample size. We only used 20 endometrial 
samples (n=20), 10 endometriosis samples and 10 normal fertile control 
endometrial samples. With not enough available collected samples from 
surgery, a small sample size may have provided a lack of variety in our data 
as well as questionable validity and reliability in our findings. The availability of 
samples was dependent on suitable surgeries occurring during the week. 
We were also limited in using IHC (Immunohistochemistry) in our laboratory 
work when validating our bioinformatics results. This is a form of qualitative 
analysis which may be more subjective (object of visually scoring slides may 
be scored differently between other assessors) than quantitative forms of 
analysis such as Reverse Transcription Polymerase Chain Reaction (PCR) or 
Western Blotting.  
We also did not use ectopic lesion samples out of the 10-endometriosis 
samples we had. We only used full thickness and pipelle samples from the 
eutopic endometrium. Studies have proposed the structure and function of 
endometrial ectopic lesions may differ from that of the eutopic endometrium in 
patients with endometriosis.  
And finally, we failed to conduct any in-vitro functional work on our desired 
transcription factor or any of the genes we found to be up regulated within 
endometriosis. We therefore were unable to discover experimentally if FOXD3 
or any of the up-regulated genes obtained from our bioinformatics findings 
had an effect on the endometrial function in cultured cells.  
Considering all these deficiencies, we have proposed potential experimental 
improvements as well as possible future work. This would look to build upon 
the findings we have obtained, and launch a further study into how FOXD3 
and genes/protein we found to be up regulated could play a role in the 
 140 
pathogenesis of endometriosis as well as possibly involvement in a target for 
therapeutic or treatment purposes. 
4.6- Potential experiment improvements and Future work 
4.6.1-How can the Bioinformatics study be extended? 
In conclusion, I felt we conducted a comprehensive bioinformatics approach 
on the collated data we inputted. In learning and understanding all of the 
relevant software before we used it, we were able to appreciate the relevance 
of the data and analysis produced. However improvements could have been 
made. 
 
There could have been a greater use of sophisticated network analysis tools 
after obtaining the networks of genes/proteins during Ingenuity. These 
network analysis tools would be used to separate the protein-interaction and 
gene-interaction within the mapping system.  
 
Analysis tools may have been used to perform an analysis of the topology of 
the resultant network finding the hub and shortest path in the network. This 
would all contribute to an increased understanding of pathological pathway 
processes during endometriosis and a more specific interaction of the 
genes/proteins involved. 
 
Cytoscape, which has numerous useful analytical plugins could have been 
used to analyze the inputted data. Like Ingenuity, Cytoscape provides a 
powerful visual mapping system across networks of data, as well as molecular 
and genetic interaction data sets in many formats. 
String software could have been used to compliment our findings. String is a 
software program that is able to integrate interaction data from 
a database of known and predicted protein interactions. The interactions 
include direct (physical) and indirect (functional) associations and are derived 
from genomic context, highly throughput experiments and conserved co- 
expression. This software program is able to use other species information 
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through orthology to human proteins and this may help obtain clues that were 
missed due to an absence of information for humans.  
Overall, a fundamental improvement would be to achieve further experiment 
validation of our bioinformatics analysis. Upon achieving this, we can return to 
input these findings back into the computational technology system networks.  
4.6.2-How can the IHC study be improved? 
We can propose improvements for any future study relating to FOXD3 and 
endometriosis. Improved experimental work can be combined with a stronger 
bioinformatics approach to obtain more insightful findings in the future with the 
purpose of gaining further understanding into the pathogenesis of 
endometriosis. Future work can also use our bioinformatics and experimental 
findings to investigate potential improvements in therapeutic and treatment 
targets.  
The sample size would need to be increased from 20 endometrial samples to 
a much larger number. This sample size increase would provide more 
strength to our findings. With a larger sample size, more accurate quantitative 
statistical analysis can be achieved on the larger dataset. Additionally, with a 
larger endometrial sample size, there would be a more diverse set of 
endometriosis samples at different stages of the disease. Therefore, with a 
larger sample of patients with endometriosis at different stages, genetic and 
molecular changes could be grouped to the different stages of the disease 
and a more detailed study can be made into the pathogenesis.  
It is also important in future work on FOXD3 that samples from ectopic 
endometrial lesions are used. Many studies have outlined functional 
differences in the eutopic endometrium compared ectopic lesions found in 
patients with endometriosis. Ota et al in 2000 through immunohistochemistry, 
found there to be COX-2 staining in the endometriotic tissue implanted on the 
ovaries. (145) The study reported that there had been larger amounts of 
prostaglandin (of which is controlled by COX-2) produced in ectopic 
endometrial tissue in endometriosis. (145) As understood from our study, 
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FOXD3 is a transcription factor for the enzyme PTGS2 (also known as COX-
2). Hapangama et al in 2010 investigated how ectopic endometriotic lesions 
have excess proliferative potential in the baboon model, and in the eutopic 
endometrium the changes were induced by the development of 
endometriosis. (146) 
Therefore further work of FOXD3 would benefit from investigating its 
expression in both the eutopic and ectopic endometrium of endometriosis 
samples. 
4.6.3- Alternative experimental methods 
Alternative methods to validate our IHC data would also be important to 
further confirm our findings in the pathogenesis of endometriosis. Western 
Blotting is an analytical technique used to detect specific proteins in a sample 
through gel electrophoresis, separating native and denatured proteins. A 
specific antibody would then be used as a probe towards this target protein 
(FOXD3).  
 Reverse Transcription Polymerase Chain Reaction (PCR) is a technique 
used to generate many copies of a DNA sequence after it has been reversely 
transcribed into its DNA complement from the RNA stand. The 
complementary DNA (cDNA) is then amplified using standard PCR.  
Both methods would be used to conduct In-Vitro work on endometrial cells in 
culture, to view if FOXD3 has an effect on the endometrial cell function. IHC 
was able to show the increased expression of FOXD3 in patients with 
endometriosis and at certain times in the cycle in the normal endometrium. 
However, in-vitro work on live FOXD3 cultured cells would take the 
investigation a step further and study the exact effect of this transcription 
factor on the structure and function of endometrial cells, especially in patients 
with endometriosis.  
Also, the expression and effects of FOXD3 in endometriosis could also be 
tested on animal models. Many studies, such as that of Hapangama et al in 
2010 and others, have obtained conclusive and successful findings from 
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studying the aberrant expression of certain proteins in the eutopic and ectopic 
endometrium in a baboon endometriosis model. (38) Other studies such as 
that of Wilkosz et al in 2011 used enhanced green fluorescent protein in mice 
with endometriosis to investigate cell attachment, invasion and vascular in-
growth. (147) Therefore, further experimental work with animal models will 
also provide further confirmation to any bioinformatics findings.  
 
4.6.4-Study of other transcription factors identified in the bioinformatics 
approach 
Cepba (C/enhanced binding protein) and HLF (Hepatic Leukaemia Factor) 
were both other notable transcription factors identified from Opossum to 
regulate the large set of up regulated genes/proteins during endometriosis 
and the related pathological processes. These can be investigated in future 
work, studying their relation to endometriosis and the expression with the 
endometrium.  With an existing study investigating the regulation of p450 
aromatase in endometriotic and endometrial stromal cells by Cepba, 
investigations could be formulated to discover if there is any the involvement 
experimentally of HLF in endometrial and endometriotic cells.  
 
4.7- Final Discussion 
In regards to future studies, we propose bioinformatics to systematically 
collate available evidence and predict the involvement of further key players. 
The combination of a bioinformatics approach and laboratory studies would 
make future studies in the pathogenesis of endometriosis and other diseases 
more effective and efficient in providing an understanding for the wider public 
and those affected.  
Our bioinformatics work was able to show how certain genes were up 
regulated in common pathological processes during endometriosis, and how 
these genes and processes were interlinked. The software programs such as 
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Ingenuity and Genevestigator were able to show the expressional pattern of 
the genes in the pathological processes within endometriosis and compare 
the up-regulation of these genes to similar expressional patterns in conditions 
such as gastric cancer. The identification of the common regulatory 
transcription factor FOXD3 through Opossum provided a breakthrough in 
pinpointing a key player involved in the gene regulation. 
Through findings from experimental work, FOXD3 was expressed in the 
glandular and luminal epithelial cells of the proliferative endometrium. In 
endometriosis, there was an increase in the expression of FOXD3 in the 
glandular and luminal epithelial cells of the secretory endometrium. The 
findings in our thesis support the idea of the increase in expression of FOXD3 
corresponding to the up regulation of the important and well known genes the 
factor regulates in the nucleus of the glandular and luminal epithelial cells 
during transcription. We were therefore able to show how FOXD3 is a key 
player in the pathogenesis of endometriosis through its aberrant expression in 
patients with the disease.  
As mentioned earlier, extensive future work is needed for FOXD3 and its 
potential effects on the function of the endometrium in patients with 
endometriosis. With an aim of discovering future details regarding the 
pathogenesis of endometriosis, future work involving FOXD3 and a 
bioinformatics approach is important in studying how the transcription factor 
may be targeted for therapeutic use. Potential future discoveries can be 
integrated into clinical settings, being used during treatment targets, therefore 
providing a greater advance in the progression of combating endometriosis.  
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